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ABSTRACT 
Due to the increased consumption of unhealthy foods rich in sugar and fat along with a 
highly sedentary lifestyle the prevalence of obesity has steadily increased in the United 
States and the rest of the world. In America about one third of the adult population is obese 
putting them at a greater risk for diseases such as cancer, cardio-vascular disorders, 
inflammation and metabolic diseases such as diabetes and non-alcoholic fatty liver disease 
(NAFLD).  NAFLD can be classified into two major categories non-alcoholic fatty liver 
(NAFL) and non-alcoholic steato-hepatitis depending on the extent of damage which 
ranges from simple fat accumulation (steatosis) to fibrosis and cirrhosis.  The major 
concern with this disease is that it is largely asymptomatic. About 25% of adult Americans 
have a fatty liver. High fat diet and common environmental pollutants such as 
trihalomethanes can act as an important predisposition for the progression of NAFLD. 
Although there have been reports of fatty liver and intestinal inflammation and 
carcinogenesis, the exact mechanism for this process remains largely elusive. In this study, 
I looked at the mechanisms of the cation channel Purinergenic receptor X7 (P2X7r) in liver 
inflammation and fibrosis and subsequent ectopic crosstalk between the liver and the 
intestines. Bromo-dichloromethane (BDCM) metabolism in the liver hepatocytes activated 
P2X7r channels in the hepatic stellate cells inducing GLUT4 expression and translocation 
leading to increased intracellular glucose levels via AKT phosphorylation. Increased 
glucose consumption activated the stellate cells causing extensive fibrosis and scarring. 
vi 
 
Simultaneously the liver resident macrophages (Kupffer cells) underwent pyroptosis by 
NLRP3 inflammasome assembly releasing damage associated molecular patterns 
(DAMP’s) such as High mobility group box 1 (HMGB1) into circulation. HMGB1 thus 
released could bind to and activate receptor for advanced glycation end products (RAGE) 
in the intestines. Activated RAGE in-turn could recruit the NADPH oxidase enzyme 
complex at the cell membrane generating peroxynitrite in association with the nitric oxide 
synthase. Peroxynitrite could recruit Toll like receptor 4 (TLR-4) to the lipid rafts via AKT 
phosphorylation. Upon membrane recruitment TLR-4 could itself bind to excess HMGB1 
in circulation leading to inflammation by TLR4 signaling. Thus, this study sheds new light 
on a mechanism of cross talk between two organ systems and opens new avenues to use 
therapeutic interventions for liver fibrosis and ectopic inflammation. 
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CHAPTER 1 
INTRODUCTION 
Obesity is a worldwide pandemic. Over the last decade due to consumption of unhealthy 
diet and increasingly sedentary lifestyle the number of obese individuals has increased 
tremendously across the world. In the U.S. alone more than one third of the adult population 
is obese(1). Built environment and Socio-economic status has played a critical role in the 
rise of obese patients in the U.S. Obesity is associated with a myriad of health 
complications such as hypertension, coronary heart diseases, stroke, sleep apnea, cancer 
and metabolic diseases such as type 2 diabetes and non-alcoholic fatty disease (2, 3).  
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver 
disease in the world due to the rising levels of obesity and metabolic disorders (4). NAFLD 
is described as the over accumulation of lipids (>5%) in the liver which is not brought 
about by the consumption of alcohol (1). The prevalence of NAFLD in the U.S. is between 
20- 30%, and 80-90% of obese adults, 30-50% in patients with diabetes and up to 90% in 
patients having hyperlipidemia. In children, the prevalence of NAFLD is 3-10% rising up 
to 40-90% in obese children (5). NAFLD is categorized depending on the underlying 
histological characteristics from simple fat accumulation (steatosis) known as a fatty liver 
to inflammation and fibrosis forming scar tissue a state known as non-alcoholic 
steatohepatitis (NASH). Most patients largely go undetected as the disease is asymptomatic 
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and patients feel fine until they develop irreversible liver damage (6). Obesity is associated 
with elevated circulating levels of pro inflammatory factors such as hormones and 
cytokines such as Tumor necrosis factor (TNF-α), Interleukin 1 (IL-1) and Interleukin 6 
(IL-6) (7). Insulin resistance (IR) plays an important role in aggravating this process by 
decreasing insulin dependent lipolysis, increasing the levels of free fatty acids (FFA). 
Leptin is a hormone released by the adipocytes that can act as a cytokine, it is the satiety 
hormone that regulates the levels of stored fat. NAFLD is associated with leptin resistance 
(8). Increased circulatory leptin increases inflammation and activates hepatic stellate cells 
resulting in fibrosis and scarring (9). 
According to the multiple hit theory, a steatotic liver is more prone to secondary 
assaults such as gut bacteria, redox stress, mitochondrial dysfunction, environmental 
pollutants, etc (10). Air particulate matter < 2.5µm size, mainly constituted by organic and 
elemental carbon, sulfates and nitrates which are the common air pollutants has shown to 
work synergistically with high fat diet to induce metabolic syndrome (11). Mice exposed 
to similar size of air particulate matter for extended periods showed increased 
inflammation, hepatic lipid accumulation, increased plasma tri-glycerides, low/very low-
density lipoproteins (LDL/VLDL), reduced glycogen storage indicating an altered glucose 
metabolism. Studies by Zheng et al showed that although a short exposure to atmospheric 
levels of these air pollutants only caused low grade liver inflammation however when this 
exposure was prolonged, it activated hepatic Kufpper cells, inducing an inflammatory 
response. This is mediated through c-Jun N-terminal Kinases (JNKs)-activator protein 1 
(AP1), nuclear factor-κB (NF-κB) and Toll-like receptor 4 (TLR4) activation. Along with 
the activation of various inflammatory signaling pathways, there is deregulation of 
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peroxisome proliferator-activated receptors (PPAR’s) (12). PPAR’s are mainly responsible 
for maintenance of fatty acid oxidation, anti-inflammatory responses and and maintaining 
lipid and glucose homeostasis in Kupffer cells, hepatocytes and the hepatic stellate cells 
(13). Another class of compounds known as dioxins commonly formed during incarnation 
of industrial and domestic waste are also able to induce steato-hepatitis (14).  The liver 
plays a major role in detoxification of many drugs, hormones and environmental toxins in 
contaminated water and food. Pesticides, heavy metals, trihalomethanes and many others 
are detected in water sources and/or in food which are known to cause NAFLD and NASH 
(15). Trihalomethanes (THMs) are short lived halogenated compounds which are formed 
when disinfectants such as chlorine interact with natural organic matter. 
Bromodichloromethane (BDCM), trichloromethane (TCM), dibromochloromethane 
(DBCM) and tribromomethane (TBM) are four THMs commonly found in chlorinated 
water and humans are exposed to them through ingestion, inhalation and direct contact as 
THMs may enter human body through drinking water, showering, swimming, etc (16). 
Since the liver is metabolizes most of the xenobiotic compounds absorbed by the gastro-
intestinal tract it is the primary site for THM exposure. Previous reports from our lab show 
that low acute exposure of Brono-dichloro methane (BDCM) in high fat diet fed mice 
generated oxidative stress mediated by CY2E1 metabolism in the liver. Increased hepatic 
leptin due to prevalent obese conditions along with BDCM induced oxidative stress 
augmented hepatic inflammation, activated Kupffer cells, hepatic stellate cells leading to 
fibrogenesis and NASH progression. BDCM treated mice also show a dysregulation of 
glycolytic pathways and an increase glucose transport resulting in dyslipidemia and NASH 
development (17-19). Several reports suggest increased levels of free glucose result in 
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activating hepatic stellate cells leading to hepatic injury and scarring (20, 21). Purinergic 
receptor X7 (P2X7r) is a cation gated ion channel that is a key modulator in liver fibrosis 
and inflammation (22). P2X7r can activate hepatic stellate cells in progressive NAFLD 
(23), In the second chapter of this thesis, I explored the mechanisms by which P2X7r is 
able to increase glucose consumption in hepatic stellate cells thereby activating them by 
inducing and translocating GLUT4 to cell surface (24).  
Liver resident macrophages (Kupffer cells) constitute about 80-90% of all tissue 
macrophages in the body (25). Kupffer cells are central to innate immunity and rapidly 
recognize potential danger from various endogenous and exogenous sources to undergo 
activation. Activated Kupffer cells interact with hepatocytes and other cells by release of 
various cytokines, chemokines, Damage associated molecular patterns (DAMP’s) (26) 
Pathogen associated molecular patterns (PAMP’s) such as lipopolysaccharides (LPS) on 
bacterial cell surface can also trigger Kupffer cell activation due to increased permeability 
of the intestinal barrier in NAFLD (27, 28). P2X7r is up-regulated in response to LPS and 
endogenous ATP (29). Though there are reports of P2X7r and liver injury in 
acetaminophen hepatoxicity and Carbon-tetrachloride mediated NASH (30, 31), the 
involvement of P2X7r of Kupffer cells is not well studied. In the third chapter, I show that 
P2X7r activation by LPS and ATP can induce the NLRP3 inflammasome leading to release 
of High mobility group box 1 (HMGB1) protein via pyroptosis a unique form of cell death, 
dependent on the activation of Caspase 1 and release of cytokines IL-1β and IL-18 (32) in 
Kupffer cells.   
HMGB1 is a chromatin binding protein which interacts with the nucleosome, 
transcription factors and histones (33). HMGB1 binds to a distorts DNA facilitating the 
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binding of other proteins. HMGB1 is now considered as a cytokine because it is secreted 
by activated macrophages, activating inflammatory responses in immune and endothelial 
cells and transduces cellular signals by binding to cell surface receptors such as receptor 
for advanced glycation end products (RAGE) and toll like receptors TLR2 and TLR4. 
Activated macrophages secrete HMGB1 as a delayed mediator of inflammation (34). 
Downstream signaling by binding to either RAGE or TLR4 leads to NFκB activation 
releasing inflammatory cytokines such as IL-1β and IL-6 (35). Interestingly NADPH 
oxidase (NOX2) activation produces peroxynitrite which recruits TLR-4 to the lipid rafts 
enhancing TLR4 signaling and cytokine release (36). In my fourth chapter, I have shown 
that endogenous HMGB1 selectively binds to and activates RAGE receptors in the 
intestines. Activated RAGE receptor can recruit the subunits of NOX2; p47Phox to the cell 
membrane activating it. Activated NOX2 then forms peroxynitrite recruiting TLR-4 to the 
cell membrane where it can further bind to HMGB1 or exogenous LPS, leading to 
downstream inflammatory signaling cascade. The liver is known as the secondary 
metastatic site for colon carcinoma however there are very few reports exploring the ability 
of a diseased liver to communicate and affect distant organs such as the intestines. Thus, 
my research provides a novel mechanism showing the effects of a fatty liver on other 
organs in obese individuals. Identifying HMGB1 as a key cytokine in ectopic inflammation 
in NAFLD can help in development of novel therapeutics such as use of HMGB1 
antibodies along with antagonists /inhibitors for TLR-4 and RAGE for management and 
control of NAFLD progression. 
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CHAPTER 2 
PURINERGIC RECEPTOR X7 MEDIATES LEPTIN INDUCED GLUT4 
FUNCTION IN STELLATE CELLS IN NON-ALCOHOLIC 
STEATOHEPATITIS1 
 
 
  
                                                          
 
1Chandrashekaran V, Das S, Seth RK, Dattaroy D, Alhasson F, Michelotti GA, 
Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. Purinergic receptor X7 mediates 
leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis. Biochim 
Biophys Acta 1862 (1): 32-45, 2016. 
       Reprinted here with the permission of the publisher. 
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Abstract: 
Metabolic oxidative stress via CYP2E1 can act as a second hit in NASH progression. Our 
previous studies have shown that oxidative stress in NASH causes higher leptin levels and 
induces purinergic receptor X7 (P2X7r). We tested the hypothesis that higher circulating 
leptin due to CYP2E1-mediated oxidative stress induces P2X7r. P2X7r in turn activates 
stellate cells and causes increased proliferation via modulating Glut4, the glucose 
transporter, and increased intracellular glucose. Using a high fat diet-fed NAFLD model 
where bromodichloromethane (BDCM) was administered to induce CYP2E1-mediated 
oxidative stress, we show that P2X7r expression and protein levels were leptin and 
CYP2E1 dependent. P2X7r KO mice had significantly decreased stellate cell proliferation. 
Human NASH livers showed marked increase in P2X7r, and Glut4 in α-SMA positive 
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cells. NASH livers had significant increase in Glut4 protein and phosphorylated AKT, 
needed for Glut4 translocation while leptin KO and P2X7r KO mice showed marked 
decrease in Glut4 levels primarily in stellate cells. Mechanistically stellate cells showed 
increase in phosphorylated AKT, Glut4 protein and localization in the membrane following 
administration of P2X7r agonist or leptin+P2X7r  agonist, while use of P2X7r antagonist 
or AKT inhibitor attenuated the  response suggesting that leptin-P2X7r axis in concert but 
not leptin alone is responsible for the Glut4 induction and translocation. Finally P2X7r-
agonist and leptin caused increase in intracellular glucose and consumption by increasing 
the activity of hexokinase. In conclusion, the study shows a novel role of leptin-induced 
P2X7r in modulating Glut4 induction and translocation in hepatic stellate cells, that are 
key to NASH progression. 
2.1 INTRODUCTION 
There has been a recent emphasis on the role of CYP2E1 in the development of 
nonalcoholic steatohepatitis, a progressive liver disease arising from a pronounced obese 
phenotype and a fatty liver (18, 37-40). CYP2E1 has been found to generate metabolic 
oxidative stress, a known “second hit” for the progression of NASH from benign steatosis 
(41). Interestingly, steatosis has been shown to be protective but a series of concomitant 
conditions like formation of free radicals, oxidative stress driven cytokine increase drives 
a inflammatory phenotype in the fatty liver (30, 42-44). NASH is characterized by severe 
metabolic disturbances that include hepatic insulin resistance, higher leptin, glucose 
intolerance and disturbances in lipid metabolism (45-47). NASH also is often associated 
with fibrotic phenotype due to increased proliferation and altered morphology of stellate 
cells (48, 49). Stellate cells that are residents of the “space of Disse” are specialized cells 
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for fat storage and lose their stored lipids to obtain a fibroblastic lineage during the 
progression of NASH (50).  
Hepatic insulin resistance is a common occurrence in NASH and insulin signaling 
is defective in most cell types in the liver (51, 52). Though liver insulin resistance is 
common, stellate cells have been shown to utilize glucose rapidly during their proliferative 
phase (53, 54). The lack of insulin signaling or mechanisms of selective insulin response 
in the stellate cells has been unclear. Though selective insulin signaling has been shown to 
be preserved in adipocytes by the way of differential responses of GLUT4 translocation 
and lipogenesis via nuclear expulsion of FoxO1, alternative routes of mediators of GLUT4 
translocation has been unknown (55). Insulin effects on GLUT4 translocation has been 
primarily found to be AKT phosphorylation mediated while defects of the insulin signaling 
process has been found to completely abrogate glucose utilization in the adipocytes (55). 
There is a significant knowledge gap in understanding alternative signaling mediators in 
mediating GLUT4 translocation, induction and increased intracellular glucose transport 
especially in NASH.  
Leptin resistance is common in human NASH (56). We and others have shown that 
CYP2E1-derived oxidative stress increases leptin levels in the liver, induces NADPH 
oxidase derived protein free radicals (57, 58). Leptin also has been shown to be a key driver 
of stellate cell activation, proliferation and fibrosis in NASH (59, 60). Leptin is also 
responsible in GLUT4 translocation and glucose uptake in stellate cells and cells of 
neuronal origin though the exact pathways and molecular mediators of its function are 
largely elusive (54, 61). Our recent laboratory observations coupled with several other 
reports of the role of purinergic receptors, in causing Kupffer cell activation, autophagy 
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and NASH progression have thrown important light on the role of these innate immune 
mediators in NASH (23, 31, 62, 63). P2X7 receptors are ion channels responsive to high 
concentrations of ATP that is released following cellular necrosis (23, 64). P2X7 receptors 
upon activation are known to perform several important cellular tasks including caspase-1 
dependent IL1β production and in lipid metabolism (23, 65). The P2X7 receptor (P2X7r) 
is one such multifunctional protein that is related to multiple partners and signaling 
pathways (66). The P2X7r-lipid metabolism pathway is related to many biological 
functions of P2X7R, such as cell death and pathogen clearance (67). This signaling 
pathway may be involved in many functions that are dependent on bioactive lipids, 
activation of the different cellular signaling pathways that may mimic insulin signaling and 
provide an explanation to the differential behavior of stellate cell glucose transport and 
proliferative responses even in a state of profound insulin resistance (68). 
In this study we hypothesize that CYP2E1 driven oxidative stress and increased 
leptin results in P2X7r induction and concomitant activation leading to AKT pathway 
activation.  The increased phosphorylation of AKT leads to GLUT4 translocation to the 
stellate cell membranes resulting in increased intracellular glucose and stellate cell 
activation in NASH. We use a diet induced obese mouse model to have a fatty liver 
phenotype (Simple steatosis) with no inflammation or fibrosis (NAFLD group) (69). 
CYP2E1 mediated oxidative stress is generated by administering a hepatotoxin 
bromodichloromethane (BDCM). We chose to use the steatosis stage of NAFLD with no 
inflammation or fibrosis to demonstrate the effect of metabolic oxidative stress and its 
consequences. 
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Our results from both in-vivo (mouse model of NAFLD) and in-vitro models (rat 
stellate cells) show that increased leptin due to CYP2E1 derived oxidative stress induce 
P2X7r and activates it resulting in increased GLUT4 protein levels in stellate cells. The 
GLUT4 translocation is also increased in these cells following co-incubation with P2X7r 
agonist and is mediated by AKT phosphorylation. The above mechanisms suggested that 
leptin induced P2X7r activation might be key to the glucose utilization and high energy 
demand for proliferating stellate cells. 
2.2 MATERIALS AND METHODS 
Mice model for NAFLD: Pathogen-free, adult, male mice with C57BL/6J background 
(Jackson Laboratories, Bar Harbor, ME) were used in the study. They were fed with a high-
fat diet (60% kcal fat) from 6 wk to 16 wk and used as a model of nonalcoholic fatty liver 
disease (NAFLD). All experiments were conducted at the completion of 16 wk. The 
animals were housed one in each cage before any experimental use. Mice that contained 
the deleted purinergic receptor X7 gene (P2X7r KO) (B6.129P2-P2rx7tm1Gab/J) and mice 
that contained the disrupted OB gene (leptin) (B6.V-Lep<ob>/J) (Lep KO) were purchased 
from Jackson Laboratories. All groups of mice were fed with a high-fat diet and treated 
identically to NAFLD mice. All groups of mice had ad libitum access to food and water 
and were housed in a temperature-controlled room at 23–24°C with a 12-h:12-h light/dark 
cycle. All animals were treated in strict accordance with the NIH Guide for the Humane 
Care and Use of Laboratory Animals, and the experiments were approved by the 
institutional review boards at NIEHS, Duke University, and the University of South 
Carolina at Columbia. The high fat diet was procured from Research Diet Inc, USA 
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Induction of liver injury in obese mice (Toxin Model): NAFLD mice or high-fat diet 
fed gene specific knockout mice (P2X7r KO and Lep KO) were administered with 
bromodichloromethane (BDCM) (1.0 mmol/kg, diluted in olive oil) through the 
intraperitoneal route twice a week for 4 weeks to assess the effects of chronic exposure of 
BDCM (NAFLD+BDCM, P2X7r KO and Lep KO). However, NAFLD mice treated with 
olive oil (diluent of BDCM) were used as control (NAFLD). After completion of the 
treatment, mice of all study groups were sacrificed for liver tissue and serum for the further 
experiments.  
Inhibition of CYP2E1 by diallyl sulfide: A set of high-fat diet fed, BDCM treated mice 
(NAFLD+BDCM) were administered with 50mg/kg diallyl sulfide (diluted in corn oil) via 
intraperitoneal injection, twice a week for 4 weeks. This group of mice was referred as 
DAS. 
Immunohistochemistry: Formalin-fixed, paraffin-embedded liver tissue from all the mice 
groups were cut into 5 μm thick tissue sections. Each section was deparaffinized using 
standard protocol. Briefly, sections were incubated with xylene twice for 3 min, washed 
with xylene:ethanol (1:1) for 3 min, and rehydrated through a series of ethanol (twice with 
100%, 95%, 70%, 50%), twice with distilled water, and finally rinsed twice with PBS 
(Sigma-Aldrich). Epitope retrieval of deparaffinized sections was carried out using epitope 
retrieval solution and steamer (IHC-World, Woodstock, - MD) following the 
manufacturer's protocol. The primary antibodies anti-P2X7r, anti-α- SMA and anti-GLUT4 
were purchased from Abcam (Cambridge, MA) and used in 1:250 dilutions. Antigen-
specific immunohistochemistry were performed using Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) following manufacturer's protocols. 3,3' Diaminobenzidine 
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(Sigma-Aldrich) was used as a chromogen substrate. Sections were counter-stained by 
Mayer's hematoxylin (Sigma-Aldrich). A double stain IHC was performed for dual labeling 
of GLUT4 and α SMA using the MULTIVIEW® (mouse-HRP/mouse-AP) IHC kit from 
Enzo life Sciences (Farmingdale, NY). The sections were deparaffinized as described 
above and staining was performed according to manufacturer’s instructions. Washing with 
PBS (Sigma-Aldrich) was performed thrice between the steps. Sections were mounted in 
simpo mount (GBI Laboratories, Mukilteo, WA) and observed under a 20X oil objective. 
Morphometric analysis was done using CellSens Software from Olympus America. 
Quantitative RT-PCR: Gene expression levels in tissue samples were measured by two-
step qRT-PCR. Total RNA was isolated from liver tissue and cells grown in a monolayer 
by homogenization in TRIzol reagent (Invitrogen) according to the manufacturer's 
instructions and purified with the use of RNeasy mini kit columns (Qiagen, Valencia, CA). 
Purified RNA (1 μg) was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad) 
following the manufacturer's standard protocol. qRT-PCR was performed with the gene-
specific primers using SsoAdvanced SYBR Green supermix (Bio-Rad) and CFX96 thermal 
cycler (Bio-Rad). Threshold Cycle (Ct) values for the selected genes were normalized 
against 18S (internal control) values in the same sample. Each reaction was carried out in 
triplicate for each gene and for each tissue sample. NAFLD mouse liver sample was used 
as the control for comparison with all other liver samples form study groups of mice. The 
relative fold change was calculated by the 2−ΔΔCt method. The sequences for the primers 
used for real-time PCR are provided in Table1. 
Immuno Blotting: Tissue (30 mg) from each liver sample was homogenized in 500 μl of 
RIPA buffer (Sigma-Aldrich) with protease inhibitor (1X) (Pierce, Rockford, IL) using 
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dounce homogenizer. For cells growing in monolayer were harvested using 0.05% Trypsin-
EDTA (Gibco) and lysed in MPER lysis buffer (100µL) (Thermo-Scientific). The lysate 
was sonicated using the branson ultrasound sonicator. The homogenate was centrifuged 
and supernatant used for SDS PAGE western blotting. 30 µg of protein from each sample 
was loaded on Novex (Invitrogen, Carlsbad, CA) 4–12% bis-tris gradient gel and run for 
completion of SDS PAGE. Resolved proteins bands were transferred to nitrocellulose 
membrane using precut nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories, 
Hercules, CA) and Trans-Blot Turbo transfer system (Bio-Rad) in case of low molecular 
weight proteins and using wet transfer module from Invitrogen in case of high molecular 
weight proteins. A solution of 5% non-fat milk was used for blocking. Primary antibodies 
against α-SMA, GLUT4, p-AKT and β-actin, Total AKT (all were purchased from 
Abcam), at recommended dilutions, and compatible horseradish peroxidase-conjugated 
secondary antibodies were used. Pierce ECL Western Blotting substrate (Thermo Fisher 
Scientific, Rockford, IL) was used. The blot was imaged using G:Box Chemi XX6  
(Syngene imaging systems) and subjected to densitometry analysis using Image J. 
Cell culture and treatments: Immortalised rat hepatic stellate cell line (8B) kindly 
provided to us by Dr. Anna Mae Diehl (Duke-Gastroenterology), were maintained in high 
glucose Dulbelccos modified eagles medium (DMEM), Corning (Tewksbury, MA) 
supplemented with 10% fetal bovine serum (FBS), Atlanta biologicals (Norcross, GA) 
suplimented with 2mM glutamine, 100U/ml Penicillin, and 100μg/ml streptomycin; Gibco 
(Grand Island, NY) at 37oC in a humidified atmosphere of 5% CO2.  The cells were then 
treated with Leptin 100ng/ml, Biovision (Milpitas, CA) (Lep), Benzoyl ATP as P2X7r 
Agonist (P7 Ag), 50µM P13K inhibitor (LY294002) (AKTi) and 100µM P2X7r 
15 
 
Antagonist (A438079) (P7 An), separately or in combination with Leptin and Benzoyl ATP 
(Lep+P7 Ag), Leptin and A438079 (Lep+P7 An), Leptin and LY294002 (Lep+AKTi), 
Leptin and Benzoyl ATP and LY294002 (Lep+P7 Ag+AKTi) for 48 h and processed for 
future experiments. The inhibitors and agonist were purchased from SantaCruz 
Biotechnology (Dallas, TX). Freshly isolated rat hepatocytes (TRL, Research triangle park, 
NC) were incubated with high glucose DMEM media supplemented with 10% FBS and 
exposed to 100μM BDCM for 48 h at 37oC in a humidified atmosphere of 5% CO2. The 
cells were harvested and supernatant were used as a conditioned media for hepatic stellate 
cells. 8B cells were incubated with 1:5 fold diluted conditioned media (CM) alone or in 
combination with LY294002 (CM+AKTi) for 48 h and cells were used for further 
experiments.   
Immuno-fluorescence: Treated and control 8B cells were fixed in 10% Neutral buffered 
Formalin for 15 min at room temperature (RT). They were then permeablized in PBS with 
0.1% Triton X (PBSTx) for 10 min followed by blocking with PBS containing  10% fetal 
bovine serum, 3%  bovine serum albumin and 0.2% Tween 20 for 1h, then incubated with 
primary antibodies  GLUT4  and p-AKT (1:1000) diluted in blocking buffer at 4˚C 
overnight. Cells were washed thrice in PBSTx for 10 min each. The cells were then 
incubated with compatible AlexaFlour conjugated secondary antibodies 633 (red) for 
GLUT4 and 488 (green) for p-AKT from Invitrogen. (Grand Island, NY), followed by three 
washes in PBSTx for 10 min each. Finally, the cells were mounted in Prolong gold antifade 
reagent with DAPI. Images were taken under 40X objective using the Olympus BX51 
microscope. 
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Biochemical assays for intracellular glucose and hexokinase activity: Intracellular 
glucose concentration was measured using the Amplex Red Glucose/Glucose Oxidase 
assay kit (Invitrogen) and intracellular hexokinase activity was measured using Hexokinase 
colorimetric assay kit Biovision (Milpitas, CA). All procedures were followed according 
to manufacturer’s instructions. The resulting glucose and hexokinase values were 
normalized to the total protein concentration of the samples measured by Bradford’s 
reagent.  
Statistical Analyses: All experiments were repeated three times with 3 mice per group (N 
= 3; data from each group of mice was pooled). The statistical analysis was carried out by 
analysis of variance (ANOVA) followed by the Bonferroni posthoc correction for 
intergroup comparisons. Quantitative data from western blots as depicted by the relative 
intensity of the bands were analyzed by performing a student’s t test. P<0.05 was 
considered statistically significant. 
2.3 RESULTS 
P2X7r protein expression in the NAFLD liver is modulated by CYP2E1-mediated 
oxidative stress and adipokine leptin.  We have shown previously that CYP2E1-
mediated oxidative stress increases hepatic leptin and P2X7r both at mRNA and protein 
levels (57, 62). This observation was also elucidated by Ikejima K et al where CCl4, 
CYP2E1 substrate, administration increased leptin levels (58). Since leptin is shown 
previously to be aiding in stellate cell proliferation and fibrogenesis, we wanted to study 
novel downstream mechanisms of leptin action and its crosstalk with P2X7r in the liver 
(70, 71). Results showed that the immunoreactivity of P2X7r in the NAFLD liver that was 
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co-administered with the hepatoxin BDCM, a substrate of CYP2E1 showed a significant 
increase as compared to NAFLD mice alone (Figure. 2.1 A and 2.1 B) (P<0.05). Mice 
treated with CYP2E1 inhibitor diallyl sulfide (DAS) or mice that were deficient in leptin 
(Lep KO) showed a significant decrease in the P2X7r immunoreactivity 
(immunohistochemistry on liver slices) when compared to NAFLD+BDCM group (Fig. 
2.1 A and 2.1 B) (P<0.05). There was a significant increase in the mRNA expression of 
P2X7r in NAFLD+BDCM group as compared to NAFLD group alone while 
administration of DAS or use of Leptin KO mice significantly decreased P2X7r mRNA 
expression suggesting that the P2X7r protein might be intrinsic to the diseased liver 
(Figure. 2.1 C) (P<0.05). NAFLD group had significant micro and macro vesicular 
steatosis while NAFLD+BDCM group had higher macrovesicular fibrosis when compared 
to NAFLD group alone as shown by Oil Red-O stain (Figure 2.1 D). Interestingly P2X7r 
KO mice showed marked decrease in Oil Red O stain when compared to NAFLD groups. 
Leptin-induced P2X7r is required for stellate cell activation in progressive liver 
injury of NAFLD mice. Leptin has been shown to aid in the proliferation of stellate cells 
(59, 72-74). The stellate cells are crucial for the wound healing response in the liver though 
it has been shown to be involved in fibrotic pathology of progressive NAFLD and 
development of hepatocellular carcinoma (75). On the other hand P2X7 receptor activation 
has been shown to participate in NASH pathophysiology via the inflammosome formation 
but detailed mechanisms are unclear (23, 63). To study the role of leptin induced P2X7r 
activation in stellate cell proliferation in progressive NAFLD following CYP2E1 mediated 
oxidative stress, immunohistochemistry, western blot analysis and mRNA expression of 
stellate cell activation marker α-SMA were studied. Results showed that there was a 
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significant increase in sinusoidal immunoreactivity of α- SMA in NAFLD+BDCM group 
as compared to NAFLD group alone (Figure. 2.2 A and 2.2 B) (P<0.05). Use of leptin and 
P2X7r KO mice significantly decreased the immunoreactivity of α-SMA in the liver slices 
(Figure. 2.2 A and 2.2 B). NAFLD+BDCM group had a significant increase (>6fold) in α-
SMA mRNA expression as compared to NAFLD group alone while lack of leptin or P2X7r 
had significantly decreased expression of the α-SMA mRNA (Figure. 2.2 C) (P<0.05). 
Western blot analysis of α-SMA protein in liver homogenates showed a significant increase 
of the protein in NAFLD+BDCM group as compared to NAFLD group alone while use of 
liver homogenates from Leptin or P2X7r KO mice showed a significant decrease in the 
band reactivity when measured by Image J software (Figure. 2.2 D and 2.2 E) (P<0.05). 
Leptin-induced P2X7r modulates GLUT4 levels in murine NASH livers. Leptin has 
been extensively studied for its role in the energy homeostasis and metabolism (76). 
However, due to the higher levels of leptin in obese subjects as well as in fatty liver disease, 
it is unclear when and where leptin function is regulated especially in the liver (77). Stellate 
cells acquire a proliferating phenotype in liver injury and require increased glucose 
transport into the cells apart from rapid utilization of glucose to meet its energy needs (54, 
78). To show whether leptin induced P2X7r modulates GLUT4, a principal glucose 
transporter in the liver, mRNA expressions, protein levels and localization of GLUT4 were 
studied. Results showed that GLUT4 mRNA expression was significantly upregulated 
(>70 fold) in the liver of NAFLD+BDCM group as compared to NAFLD alone (Figure. 
2.3 A) (P<0.05) whereas use of P2X7r or Leptin KO mice livers had significantly decreased 
mRNA expressions of GLUT4 (Figure. 2.3 A)(P<0.05). Protein levels of GLUT4 as shown 
by western blot showed a significant increase in NAFLD+BDCM group as compared to 
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NAFLD group alone (Figure. 2.3 B and 2.3 C) (P<0.05). Use of leptin KO or P2X7r KO 
mice treated with BDCM showed a significant decrease in the protein levels of GLUT4 in 
the liver (Figure 2.3 B-2.3 E) (P<0.05). Since western analysis of GLUT4 protein in the 
liver could not help in the identity of a particular cell type where the GLUT4 expression 
might be the highest, we performed immunohistochemistry. Results showed that GLUT4 
induction was highest in the sinusoidal cells in the NAFLD+BDCM group as compared to 
NAFLD group alone (Figure. 2.3 F and 2.3 G) (P<0.05) while leptin KO or P2X7r KO had 
a significant decrease in the GLUT4 staining in these cell types. Since activated stellate 
cells have been shown to utilize higher glucose primarily through GLUT4, we studied the 
GLUT4 localization in activated stellate cells (54). Dual labelling immunohistochemistry 
(Red: GLUT4, Brown: α-SMA), showed a markedly higher number of co-localizations of 
GLUT4 protein and stellate cell activation marker α-SMA (Figure. 2.3 H) suggesting that 
the activated stellate cells might have an increased expression and levels of GLUT4 
following oxidative stress injury in progressive NAFLD model. Similar Glut4-α-SMA co-
localizations were also observed in human NASH samples when compared with human 
controls suggesting a strong correlation with the studies in mouse model of NASH (Figure 
2.3 I). Glut4 protein levels also showed a significant increase in rat hepatic stellate cells 
when stimulated with a P2X7r agonist and leptin (Figure 2.3 J) followed by a similar 
increase in P2X7r protein in these cells (Figure 2.3 K). 
Lack of Leptin or P2X7r decreases phosphorylation of AKT in oxidative stress 
induced liver injury in progressive NAFLD mice. The downstream pathways of Leptin 
and P2X7r activation have been shown to act through PI3/AKT pathway with subsequent 
phosphorylation of AKT (61, 66). Based on our previous results in this study, it was 
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important that we study AKT phosphorylation as a result of leptin induction of P2X7r and 
subsequent activation of the purinergic receptor isoform. Results showed that 
NAFLD+BDCM group had significantly higher levels of p-AKT protein as compared to 
NAFLD group alone (Figure 2.4 A-2.4 D) (P<0.05). Use of leptin KO mice or mice that 
were devoid of P2X7r showed significant decrease in the P-AKT protein levels as 
measured by western blot analysis (Figure 2.4 A-2.4 D) (P<0.05). The results suggested 
that the injured liver of NAFLD mice that had leptin induced P2X7r induction and 
subsequent activation might modulate the functions of the diseased liver via the AKT 
pathway and correlate well with the downstream events of these molecules. However, the 
suggested data is premature at this point since mere estimation of pAKT levels in the liver 
does not explain the relationship of leptin-induced P2X7 activation and the corresponding 
signaling events. To show conclusively that leptin-induced P2X7r signaling is mediated 
through AKT phosphorylation in activated stellate cells, rat myofibroblast 8B cells were 
used. Results showed that co-incubation of cells with leptin (100ng/ml) significantly 
increased AKT phosphorylation as compared to medium only group (Figure. 2.4 E.i and 
2.4 E.iii). Cells treated with P2X7r agonist Bz-ATP (P7 Ag) also increased AKT 
phosphorylation significantly when compared to controls as shown by 
immunofluorescence microscopy and morphometry (Figure. 2.4 E.i and 2.4 E .ii) (2.4 F) 
(P<0.05). The increase in AKT phosphorylation was significantly higher than the leptin 
treated cells (Figure. 2.4 E.iii) (2.4 F) (P<0.05). Use of AKT inhibitor significantly 
decreased the fluorescent intensity (Figure. 2.4 E v and vi), (The decrease was more 
pronounced in the Leptin+P2X7r agonist group than leptin or P2X7r agonist treated alone) 
in cells treated with both leptin and P2X7r agonist suggesting that P2X7r-mediated AKT 
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phosphorylation is downstream of leptin. Use of P2X7r antagonist significantly decreased 
the AKT phosphorylation induced by leptin (vii) (Figure. 2.4 F). Use of conditioned 
medium increased AKT phosphorylation (Figure. 2.4 E viii and ix) while AKT inhibitor 
significantly decreased it. The above results suggested that P2X7r mediated 
phosphorylation of AKT was (a) downstream of leptin and (b) was the principal driver of 
AKT phosphorylation since use of the agonist attenuated the phosphorylation completely. 
However, leptin-induced AKT phosphorylation is not ruled out in these cells and it is 
unclear at this point whether there is any parallel role leptin-induced AKT phosphorylation. 
P2X7r activation and subsequent AKT pathway modulates GLUT4 induction and 
translocation in stellate cells. To study the role of P2X7r-mediated signaling and the AKT 
pathway in GLUT4 induction and translocation to the membrane, a transformed rat stellate 
cell line was used. GLUT4 translocation has been shown to be a major event in glucose 
transport across the membrane and is key to increased stellate cell proliferation (54). Cells 
incubated with leptin were later fixed and immunoreactivity to GLUT4 was analyzed by 
immunofluorescence microscopy. Results showed that cells treated with leptin (Figure. 2.5 
v) or P2X7 agonist (Figure. 2.5 ii) had a significant increase in both the cytoplasmic and 
membrane localizations of GLUT4 as compared to untreated control (Figure 2.5 i) cells. 
Interestingly, cells that were incubated with both leptin and P2X7r agonist had a marked 
increase in both localization of GLUT4 in the cell membrane as well as strong protein 
levels in the cytoplasm as compared to either leptin alone or P2X7r agonist treated cells. 
The data suggested a strong synergistic effect on GLUT4 (Figure. 2.5 vi) localization and 
protein induction. Treatment of leptin-primed cells with P2X7r antagonist completely 
abrogated the GLUT4 induction and translocation (Figure. 2.5 iv and 2.5 vi). A parallel use 
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of AKT inhibitor with P2X7 agonist treated cells or with conditioned medium markedly 
decreased Glut4 protein and localization suggesting P2X7r and AKT phosphorylation 
mediated GLUT4 translocation and induction were downstream of leptin (Figure. 2.5 iv 
and 2.5 ix). To prove that the cellular microenvironment in diseased liver cross talks with 
each other in the form of paracrine fashion and influences stellate cell GLUT4 induction 
and translocation, cells were incubated with a conditioned medium that was generated by 
treating hepatocytes with BDCM. Results showed that cells treated with conditioned 
medium had marked increase in GLUT4 protein and its localization in the membrane as 
compared to medium controls (Figure. 2.5 viii) whereas, co-incubation with AKT inhibitor 
markedly decreased the fluorescent intensity (Figure. 2.5 ix), suggesting that hepatocyte-
stellate cell crosstalk might be a significant event that influences P2X7r mediation of 
GLUT4 induction and translocation to the membrane. 
P2X7r activation leads to increased intracellular glucose and hexokinase acivity in 
stellate cells. The fate of hepatic stellate cells in liver injury involves a crucial regulation 
of metabolism in these cells (79, 80). The trans-differentiation of stellate cells from a 
quiescent state to a highly proliferative state requires rapid glucose uptake and possibly a 
higher utilization of the glucose stores for enhanced glycolysis (79). To show that P2X7r 
mediated GLUT4 induction and translocation regulated intracellular glucose levels by 
increasing glucose uptake, concentrations of stellate cell glucose were estimated through a 
biochemical assay. Results showed that P2X7 agonist and leptin significantly raised 
intracellular glucose levels as compared untreated cells (Figure. 2.6 A) (P<0.05). 
Administration of P2X7r antagonist significantly decreased the intracellular glucose levels 
(Figure. 2.6 A) (P<0.05). Since hexokinase levels remain high and its activity is key to 
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glucose utilization in stellate cells for glycolytic pathway, as evidenced in situations where 
the stellate cell acquires a myofibroblastic lineage, we studied the fate of the increased 
intracellular glucose by measuring the activity of hexokinase (HK) (54). Results showed 
that co-incubation of cells with P2X7 agonist or leptin significantly upregulated the activity 
of HK by 45-50% (Fig. 2.6 B) (P<0.05), whereas administration of the P2X7r antagonist 
significantly decreased the HK activity (Figure. 2.6 B) (P<0.05). The results suggested that 
leptin and p2X7 r modulated glucose metabolic fate in stellate cells possibly by its actions 
on GLUT4 induction and translocation and the two events were closely correlated. 
2.4 DISCUSSION 
The present study shows a novel role of P2X7r in modulating GLUT4 induction and 
translocation in hepatic stellate cells. The study which uses an experimental murine model 
of NAFLD with concomitant metabolic oxidative stress as a “second hit” outlines a 
mechanistic investigation of the role of leptin, P2X7r induction, GLUT4 translocation and 
finally higher intracellular glucose in hepatic stellate cells. The study is significant since it 
identifies a new mediator for stellate cell activation and proliferation crucial for NASH 
progression. 
We and others have shown previously that metabolic oxidative stress increases 
systemic and hepatic leptin levels over and above the levels found in obesity (57, 58). 
Increased leptin can perform an array of functions or dysfunctions that affect a myriad of 
pathways causing dysregulation in immune, endothelial and metabolic functions in NASH 
(71). Leptin has been shown to cause increased GLUT4 translocation in stellate cells apart 
from its more established role of causing increased stellate cell proliferation but the 
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downstream mechanisms in metabolic alterations in these cells have been unclear (54). 
Since there are several literature reports including reports from our laboratory that suggest 
the strong involvement of P2X7r in inflammatory and cell fate regulations in the 
hepatocellular microenvironment, we argued that circulating leptin might induce P2X7r 
and leptin-mediated P2X7r activation in NASH might have a role in the metabolic 
dysregulation in the liver especially in stellate cells (62, 63). Interestingly Dranoff JA. Et 
al reported a strong involvement of P2Y receptor subtypes in activated stellate cells (81). 
The present study did not explore the role of the P2Y receptors in NASH development due 
to our earlier observations that P2X7r was crucial for NADPH oxidase induced reactive 
oxygen species generation, autophagy and altered pathogenesis in NASH. We are not 
aware of any studies that link P2Y receptors with NADPH oxidase activation in vivo. 
However, it is possible that significant crosstalk may exist among different P2 receptors 
owing to their activation by nucleosides. Our data of attenuated P2X7r protein levels in 
leptin knockout mice show the strong role of leptin in inducing these receptors in the NASH 
liver (Figure. 2.1 B and 2.1 C; >7 fold decrease in protein). However, caution needs to be 
exerted in interpretation of this particular data since the current study does not show by 
way of leptin supplementation in leptin KO mice, whether there is a strong upregulation of 
P2X7r in these livers. Our data of decreased P2X7r in DAS treated livers also correlates 
well with the argument that oxidative stress, increased leptin and P2X7r induction and/or 
activation might be strongly associated (Fig. 2.1).  
We have shown previously that P2X7r KO mice are protected from NASH 
associated fibrosis (62). In this study P2X7r knockout mice also had significantly decreased 
stellate cell activation as was indicated by decreased immunoreactivity of α-SMA in NASH 
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livers (Figure. 2.2). Stellate cell transdifferentiation from a quiescent stage to a more 
myofibroblastic lineage followed by proliferation is a significant event in NASH (79, 82). 
Studies have shown that the altered phenotype of stellate cells due to liver injury causes a 
significant alteration of its metabolic machinery which includes increased glucose 
utilization and a preferable use of the glycolytic machinery even in aerobic circumstances 
(79). The above metabolic pattern requires GLUT4 translocation to the membrane for 
transporting increased glucose into the cell (54). Leptin has been shown to be involved in 
the process of translocation of GLUT4 to the membrane but we are not aware of any studies 
that also reported its induction by leptin or its downstream mediators (54). Our study shows 
that leptin-induced P2X7r was required for induction of GLUT4 in the liver as shown by 
qRTPCR, western blot and IHC analysis since both leptin KO mice and P2X7r KO mice 
had decreased GLUT4 with P2X7r KO showing a more pronounced depletion of the 
GLUT4 immunoreactive band (Fig. 2.3 E). Interestingly P2X7r KO mice barely expressed 
GLUT4 mRNA suggesting a strong transcriptional regulation of the GLUT4 protein by 
P2X7r in the injured liver (Fig. 2.3 A). GLUT2 and GLUT4 are cellular glucose 
transporters found in the liver probably in every cell type (83, 84). Some studies suggest 
that insulin and insulin-like growth factor-1 are mitogenic for Hepatic Stellate Cells 
(HSC’s) in spite of the fact that insulin resistance is a common etiology in NASH (85-88). 
GLUT4 has been shown to be insulin responsive in hepatocytes and stellate cells and is 
tightly regulated primarily by activated PI3K (54, 83). As a response from insulin 
signaling, GLUT4 is rapidly translocated to the cell membrane to allow more glucose 
influx (61, 89). The high glucose then stimulates increased consumption in cells 
undergoing proliferation or that are in need for higher metabolic activity (90). Stellate cells, 
26 
 
due to their higher metabolic activity in injured liver are unique since NASH has 
documented insulin and leptin resistance (47). It is unclear how the stellate cells still 
respond to insulin and leptin. To prove that activated stellate cells and not any other cell 
types express higher GLUT4 in NASH liver, we conducted immunohistochemistry of 
GLUT4 (Figure. 2.3 F). Firstly, we found higher GLUT4 in sinusoidal cells and secondly, 
we observed co-localization of GLUT4 and α-SMA in the liver slices (Figure 2.3 H). The 
same results were obtained with human liver slices where NASH livers showed a marked 
increase in P2X7r (Figure 2.3 I). Importantly, Lep KO or P2X7r KO mice had significantly 
lower GLUT4 in stellate cells (Figure. 2.3 F). Based on these observations we argued that 
owing to the importance of stellate cells in an injured liver, primarily for wound healing 
response, there may be parallel (Insulin based-already known) and/or leptin-linked P2X7r-
mediated signaling pathway that help in maintaining their high metabolic activity in 
NASH. The higher metabolic activity may initiate more glucose influx into these cells 
primarily by increased GLUT4 induction and translocation. Firstly, to strengthen our 
argument for an overt role of AKT pathway downstream of leptin-P2X7r axis we 
performed in vitro experiments in rat stellate cells. Our data of attenuation of AKT 
phosphorylation by the co-incubation with P2X7r antagonist in cells stimulated with leptin 
showed that P2X7r was central to leptin-induced AKT phosphorylation (Figure. 2.4 E and 
F). Further confirmation of the role of P2X7r induced GLUT4 induction and translocation 
in stellate cells were achieved following in vitro experiments in stellate cells and 
immunofluorescence microscopy. Results showed that P2X7r agonist +Leptin had a 
marked increase in both protein levels and membrane localization of GLUT4 while use of 
P2X7r antagonist abrogated it (Figure. 2.5 vii). Incubation with a hepatocyte derived 
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conditioned medium also significantly increased induction and translocation of GLUT4, 
while use of AKT inhibitor attenuated both of these functions. It is worth mentioning that 
P2X7r has been shown to be activated by ATP released from necrosed hepatocytes 
following CYP2E1 mediated oxidative stress (30). The conditioned medium used in this 
study was also generated in the same method where BDCM was used to be a substrate of 
CYP2E1 in place of CCl4. It is justifiable to assume that the conditioned medium is a good 
example of cellular microenvironment in NASH where necrosed hepatocytes can activate 
P2X7r on stellate cells and cause their metabolic alterations, increased responsiveness to 
higher GLUT4 and stellate cell proliferation via AKT pathway. Finally, we also showed 
that P2X7r-mediated higher GLUT4 protein and translocation resulted in higher glucose 
concentration in the stellate cells and this was followed by increased glucose consumption 
only to be attenuated by use of P2X7r antagonist and AKT inhibitor. Studies have shown 
that stellate cell proliferation requires higher glucose consumption and increased 
hexokinase activity (HK) which creates a gradient that allows more glucose to be brought 
into the cell (91). Our results of increased HK activity in the stellate cells primarily by 
P2X7r activation is a strong indication of leptin-P2X7r axis in modulating stellate cell 
response in NASH though we have no direct evidence to prove this mechanism in vivo. 
Finally, our results suggested that though insulin resistance is rampant in NASH, stellate 
cells are responsive to leptin-induced P2X7r-mediated glucose influx primarily through 
induction and translocation of GLUT4. Mechanistically, the induction and translocation 
might be mediated by AKT phosphorylation initiated by P2X7r (Figure. 2.7). However, 
doubts still remain whether the AKT phosphorylation induced by insulin signaling acts in 
parallel to P2X7r or they act in concert and these two mediators are linked. Another 
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limitation in this study is the mechanism of leptin-induced P2X7r expression or activation. 
Interestingly our results show that leptin knockout mice have a significant decrease in 
P2X7r induction, a sign of a direct influence of leptin signaling on P2X7r induction. It may 
be possible that leptin-induced NADPH oxidase activation and subsequent release of 
reactive oxygen species may be responsible for P2X7 induction, a hypothesis that needs 
further exploration. The hypothesis is strengthened by the fact that invivo experiments 
suggested a parallel paracrine signaling influences Glut4 induction, an event that may see 
the involvement of oxidative stress or cell death signals like HMGB1 or extracellular ATP. 
Future studies may focus on a P2X7r dependent stellate cell circuit that can be 
pharmacologically manipulated to potentiate insulin resistance in NAFLD/ NASH patients. 
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Figure.2.1 P2X7r protein expression in the NAFLD liver is modulated by CYP2E1-
mediated oxidative stress and adipokine Leptin. A:  P2X7r immunoreactivity as shown by 
immunohistochemistry in liver slices from mice fed with high-fat diet (60% kcal fat) as a 
model of nonalcoholic fatty liver disease (NAFLD), NAFLD mice exposed to 
bromodichloromethane (BDCM) referred as NAFLD+BDCM, NAFLD mice co-exposed 
with BDCM and Diallyl sulfide, a known CYP2E1 inhibitor (DAS) and the mice deficient 
of leptin gene fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken 
at 20X magnification. B: Morphometric analysis of P2X7r immunoreactivity (mean data 
from three separate microscopic fields were plotted on Y-axis in NAFLD, 
NAFLD+BDCM, DAS and Lep KO groups of mice (*P<0.05).   C: mRNA expressions of 
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P2X7r in liver tissue of NAFLD, NAFLD+BDCM, DAS and Lep KO groups of mice as 
assessed by quantitative real time PCR, the expressions were normalized with 18s and 
compared to the NAFLD group and represented as fold changes to NAFLD (*p<0.05).   
 
Figure 2.1 D: Oil Redo staining for lipid accumulation in liver slices from mice fed with 
high-fat diet (60% kcal fat) as a model of NAFLD, NAFLD mice exposed to BDCM 
(NAFLD+BDCM), the mice deficient of P2X7r gene fed with high-fat diet and exposed to 
BDCM (P2X7r KO) and mice deficient of leptin gene fed with high-fat diet and exposed 
to BDCM (Lep KO). Images were taken at 20X magnification. 
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Figure.2.2 Leptin induced P2X7r is required for stellate cell activation in progressive liver 
injury in NAFLD mice. A: Smooth muscle actin (α-SMA) immunoreactivity as shown by 
immunohistochemistry in liver slices from mice fed with high-fat diet (60% kcal fat) as a 
model of NAFLD, NAFLD mice exposed to BDCM (NAFLD+BDCM), the mice deficient 
of P2X7r gene fed with high-fat diet and exposed to BDCM (P2X7r KO) and mice deficient 
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of leptin gene fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken 
at 20X magnification. B: Morphometric analysis of α-SMA immunoreactivity (mean data 
from three separate microscopic fields were plotted on Y-axis) in NAFLD, 
NAFLD+BDCM, P2X7r KO and Lep KO groups of mice (*P<0.05). C: mRNA 
expressions of α-SMA in liver tissue of NAFLD, NAFLD+BDCM, P2X7r KO and Lep 
KO groups of mice as assessed by quantitative real time PCR, the expressions were 
normalized with 18s and compared to the NAFLD group and represented as fold changes 
to NAFLD (*p<0.05). D:  Western blot analysis of α-SMA protein levels. Lanes 1–
4 represent NAFLD, NAFLD+BDCM, Lep KO and P2X7r KO. E: Band quantification of 
the α-SMA immunoblot in NAFLD, NAFLD+BDCM, Lep KO and P2X7r KO groups of 
mice, data was normalized against β-actin (*p<0.05). 
     
Figure.2.3 Leptin induced P2X7r modulates GLUT4 levels in murine NASH livers. A: 
mRNA expressions of Glucose transporter 4 (GLUT4) in liver tissue of NAFLD, 
NAFLD+BDCM, P2X7r KO and Lep KO groups of mice as assessed by quantitative real 
time PCR, the expressions were normalized with internal control (18s) and compared to 
the NAFLD group and represented as fold changes to NAFLD (*p<0.05).  B: Western blot 
analysis of GLUT4 protein levels. Lanes 1–3 represent NAFLD, NAFLD+BDCM and Lep 
KO respectively. C: Band quantification of the GLUT4 immunoblot in NAFLD, 
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NAFLD+BDCM, Lep KO groups of mice, data was normalized against β-actin (*p<0.05). 
D: Western blot analysis of GLUT4 protein levels in liver homogenate of NAFLD, 
NAFLD+BDCM and P2X7r KO respectively. E: Band quantification of the GLUT4 
immunoblot in NAFLD, NAFLD+BDCM, P2X7r KO groups of mice, data was normalized 
against β-actin (*p<0.05). 
 
Figure 2.3 F: GLUT4 immunoreactivity as shown by immunohistochemistry in liver slices 
from mice fed with high-fat diet (60% kcal fat) as a model of NAFLD, NAFLD mice 
exposed to BDCM (NAFLD+BDCM), the mice deficient of P2X7r gene fed with high-fat 
diet and exposed to BDCM (P2X7r KO) and mice deficient of leptin gene fed with high-
fat diet and exposed to BDCM (Lep KO). Images were taken at 20X magnification. G. 
Morphometric analysis of GLUT4 immunoreactivity (mean data from three separate 
microscopic fields were plotted on Y-axis) in NAFLD, NAFLD+BDCM, P2X7r KO and 
Lep KO groups of mice (*P<0.05). 
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Figure 2.3 H: (i-iv). Co-localization of GLUT4 (red) and α-SMA (brown) by 
immunohistochemistry in liver slices from mice fed with high-fat diet (60% kcal fat) as a 
model of NAFLD, NAFLD mice exposed to BDCM (NAFLD+BDCM), P2X7r knockout 
mice fed with high-fat diet and exposed to BDCM (P2X7r KO) and leptin knockout mice 
fed with high-fat diet and exposed to BDCM (Lep KO). Images were taken at 20X 
magnification. (v) 60X oil magnification image of NAFLD+BDCM group to represent co-
localization events of GLUT4 (red) and α-SMA (brown). The events were marked with 
black solid arrow.  
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Figure 2.3 I: Co-localization of GLUT4 (red) and α-SMA (brown) by 
immunohistochemistry in liver slices from healthy human control (i) and clinical NASH 
patient (ii). Images were taken at 20X magnification. 60X oil magnification image of 
healthy human group (iii) and clinical NASH patient (iv) to represent co-localization events 
of GLUT4 (red) and α-SMA (brown). The events are marked with a black solid arrow. 
 
Figure 2.3 J: (i) Western blot analysis for Glucose transporter 4 (GLUT4) expression in 8B 
rat hepatic stellate cells cultured in high glucose DMEM media with 10%FBS (Med ctrl) 
and treated with P2X7r Agonist 100 µM (P7 Ag), P2X7r Antagonist100 µM (P7 An), AKT 
inhibitor 50  µM, Leptin 100 ng/ml (Lep), combination of Leptin+P2X7r Agonist (Lep+P7 
Ag), Leptin+P7 Antagonist (Lep+P7 An) and Leptin+AKT inhibitor (Lep+AKTi). (ii) 
Band quantification GLUT4 immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep, 
Lep+P7Ag, Lep+P7An and Lep+AKTi groups, data was normalized against β-Actin. (iii) 
mRNA expressions of Glucose transporter 4 (GLUT4)  in cell lysates of Med Ctrl, P7Ag, 
P7An, AKTi, Lep, Lep+P7Ag, Lep+P7An and Lep+AKTi groups as assessed by 
quantitative real time PCR, the expressions were normalized with internal control (18s) 
and compared to the Med Ctrl group and represented as fold changes to Med Ctrl. 
(*p<0.05). K: i) Western blot analysis for Purinergic receptor X7 (P2X7r) expression in 
Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag, Lep+P7An and Lep+AKTi groups. (ii) 
Band quantification P2X7r immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag, 
Lep+P7An and Lep+AKTi groups, data was normalized against β-Actin. (iii) mRNA 
expressions of P2X7r in cell lysates of Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag, 
Lep+P7An and Lep+AKTi groups as assessed by quantitative real time PCR, the 
expressions were normalized with internal control (18s) and compared to the Med Ctrl 
group and represented as fold changes to Med Ctrl. (*p<0.05). 
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Figure. 2.4. Lack of Leptin or P2X7r decreases phosphorylation of AKT in oxidative stress 
induced liver injury in progressive NAFLD mice. A: Western blot analysis of p-AKT 
protein levels in liver homogenate of mice fed with high-fat diet (NAFLD), NAFLD mice 
exposed to BDCM (NAFLD+BDCM) and leptin knockout mice fed with high-fat diet and 
exposed to BDCM (Lep KO) respectively. B: Band quantification p-AKT immunoblot in 
NAFLD, NAFLD+BDCM, Lep KO groups of mice, data was normalized against Total 
AKT (*p<0.05). C: Western blot analysis of p-AKT protein in liver homogenate of 
NAFLD, NAFLD+BDCM and P2X7r Knockout respectively. D: Band quantification p-
AKT immunoblot in NAFLD, NAFLD+BDCM, P2X7r KO groups of mice, data was 
normalized against Total AKT (*p<0.05). 
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Figure 2.4 E: (i-ix). Immunofluorescence for p-AKT expression in 8B rat hepatic stellate 
cells cultured in high glucose DMEM media with 10%FBS (Med ctrl) and treated with 
P2X7r agonist 100 µM (P7 Ag), Leptin 100 ng/ml (Lep), combination of Leptin+P2X7r 
agonist (Lep+P7 Ag), Leptin+AKT inhibitor (Lep+AKTi) and Leptin+P2X7r 
Agonist+AKT inhibitor (Lep+P7 Ag+AKTi), Leptin+P7 Antagonist (Lep+P7 An), 
hepatocyte conditioned media (CM) and hepatocyte conditioned media+AKT inhibitor 
(CM+AKTi). Images were taken at 40X magnification. 
                                          
Figure 2.4 F: Morphometric analysis of p-AKT immunofluorescence (mean data from three 
separate microscopic fields were plotted on Y-axis) in Med Ctrl, P7 Ag, Lep, Lep+P7 Ag, 
Lep+AKTi, Lep+P7Ag+AKTi, Lep+P7An, CM and CM+AKTi groups. (*P<0.05).
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Figure 2.4 G: Western blot analysis of p-AKT protein levels in 8 B cell lysate of Med Ctrl, 
P7Ag, P7An, AKTi, Lep, Lep+P7Ag, Lep+P7An and Lep+AKTi groups. H. Band 
quantification p-AKT immunoblot in Med Ctrl, P7Ag, P7An, AKTi, Lep, Lep+P7Ag, 
Lep+P7An and Lep+AKTi groups, data was normalized against Total AKT. 
    
 
Figure. 2.5: P2X7r activation and subsequent AKT pathway modulates GLUT4 induction 
and translocation in stellate cells. A: (i-ix). Immunofluorescence for GLUT4 expression in 
8B rat hepatic stellate cultured in high glucose DMEM media with 10%FBS (Med ctrl) and 
treated with P2X7r agonist 100 µM (P7 Ag), P2X7r antagonist 100 µM (P7 An), AKT 
inhibitor 50 µM (AKTi), Leptin 100 ng/ml (Lep), combination of Leptin+P2X7r agonist 
(Lep+P7 Ag), Leptin+ P2X7r antagonist (Lep+P7An), hepatocyte conditioned media (CM) 
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and combination of hepatocyte conditioned media and AKT inhibitor (CM+AKTi). The 
GLUT4 has been probed with red immunofluorescence and counterstained with DAPI for 
nucleuses (blue). Images were taken at 40X magnification. B: Morphometric analysis of 
GLUT4 immunofluorescence (mean data from three separate microscopic fields were 
plotted on Y-axis) in Med Ctrl, P7 Ag, P7An, AKTi, Lep, Lep+P7 Ag, Lep+P7An, CM 
and CM+AKTi groups. (*P<0.05).   
    
Figure. 2.6. P2X7r activation leads to increased intracellular glucose and hexokinase 
activity in stellate cells. A: Intracellular glucose levels in 8B hepatic stellate cells cultured 
in high glucose DMEM media with 10% FBS (Med ctrl) and treated with P2X7r agonist 
100 µM (P7 Ag), P2X7r antagonist 100 µM (P7 An) and Leptin 100 ng/ml, (Lep) 
combination of Leptin+P2X7r agonist (Lep+P7 Ag), Leptin+ P2X7r antagonist. B: 
Intracellular hexokinase activity in 8B hepatic stellate cells in Med ctrl, P7 Ag, P7 An and 
Lep groups. The intracellular glucose levels and hexokinase activity in 8B cell groups were 
normalized against their total protein levels respectively.  
 
40 
 
Table 2.1: Table showing the primer sequences for the different targerts used in this study.
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Figure 2.7: A pictorial representation of the molecular process in P2X7r-mediated Glut4 
function in NASH hepatic stellate cells.
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CHAPTER 3 
P2X7R STIMULATED NLRP3 INFLAMMASOME MEDIATES 
PYROPTOSIS IN HEPATIC MACROPHAGES LEADS TO HMGB1 
RELEASE IN NON-ALCOHOLIC FATTY LIVER DISEASE.2 
   
  
                                                          
 
2 Chandrashekaran V, Alhasson F, Dattaroy D, Seth RK, Nagarkatti M, Nagarkatti P, 
Diehl AM, Chatterjee S P2X7R stimulated NLRP3 inflammasome mediates pyroptosis in 
hepatic macrophages leads to HMGB1 release in Non-Alcoholic Fatty liver disease. To 
be published. 
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Abstract: 
Although significant research data exist on the activation of hepatic resident macrophages 
(Kupffer cells) in the progression of NAFLD, the mechanisms for it remains largely 
elusive. The present study looked at the role of P2X7r cation channel in activating 
pyroptosis via NLRP3 inflammasome activation leading to release of damage associated 
molecular pattern HMGB1 into the extra cellular environment in these cells. This study 
used an early steatohepatitic injury model in high-fat-fed mice. Results showed that 
NAFLD mice had increased circulatory HMGB1 levels, along with higher levels of IL-1β 
compared to lean controls or P2X7r KO mice. Liver sections of the NAFLD mice showed 
successful assembly of the NLRP3 inflammasome and Gasdermin D membrane co-
localisation. Mechanistically ATP released from necrosed adjacent hepatocytes activated 
the P2X7r channels leading to the assembly of the NLRP3 inflammasome which activates 
Caspase 1, active Caspase 1 then cleaves Gasdermin D, a regulator of epithelial cell 
proliferation. Cleaved Gasdermin D then oligomerizes and forms membrane pores 
releasing HMGB1. In summary, this study shows a novel mechanism of P2X7r mediated 
DAMP release in hepatic macrophages due to an underlying condition of NAFLD. 
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3.1 INTRODUCTION 
Nonalcoholic fatty liver disease is the abnormal accumulation of fat in the liver (<5% total 
liver weight) independent of consumption of alcohol. About 30% of the adult American 
population is suspected to be affected by this disease. NAFLD is associated with 
enlargement and rupture of adipocytes releasing adipokines leading to macrophage 
recruitment and inflammation (92). Kupffer cells (KC’s) are resident liver macrophages 
located in the hepatic sinusoids and play a central role in innate immunity of the liver, they 
represent about 80-90% of all tissue macrophages in the body (93).  
Several groups including ours have shown that the activation of KC’s is an 
important step in initiation and progression of liver injury (94, 95). There is also 
considerable evidence showing that chemical depletion of KC’s can prevent the release of 
inflammatory cytokines and alleviate liver damage (96). Activated KC’s secrete a variety 
of mediators influencing inflammation and fibrosis. Interestingly, the inflammatory 
progress of the disease is regulated by secretion of IL-10 by quiescent (M2) macrophages, 
leading to apoptosis of activated macrophages (95). Stressed or dying cells release 
endogenous molecules termed as Damage associated molecular patterns (DAMP’s) which 
play a crucial role in systemic sterile inflammation. DAMP’s are intracellularly sequestered 
molecules that remain unrecognized by the immune system under normal physiological 
conditions. However, under conditions of cellular stress or tissue injury, these molecules 
are actively released by the stressed immune cells. Though innate immunity mediated 
protective inflammatory repair process is believed to be beneficial, this repair mechanisms 
can cause harm when associated with chronic inflammation. This is often associated with 
overproduction of DAMP’s resulting in acute systemic hyperinflammation (97).  
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In pathological conditions such as NAFLD, high levels of ATP are passively 
released from necrotic cells (23).  ATP, thus released can activate P2X7 receptors (P2X7r) 
via the pannexin-1 hemichannel on neighboring cells leading to a localized inflammatory 
response. P2X7r are members of the family of ionotrophic ATP gated receptors expressed 
virtually on all cells of the innate immune system. Unlike other members of the P2X family, 
the P2X7r requires higher amounts of ATP for activation. Activated P2X7r promotes 
release of pro-inflammatory cytokines such as IL-6, IL-1β. TNF-α (98). P2X7r is also able 
to induce inflammation by recruitment of the NLRP3 inflammasome complex. ATP 
mediated P2X7r stimulation leads to an efflux of K+ ions triggering the NLRP3 
inflammasome pathway (99). The NLRP3 is a cytoplasmic multiprotein complex, 
consisting of the cytoplasmic receptor NLRP3, the adaptor protein ASC and the effector 
protein pro-caspase 1. Upon activation, the different scaffold proteins are assembled 
bringing several pro-caspase sub-units close to each other. These pro-caspase 1 in close 
proximity cleave each other to release the mature or active caspase 1 (100-102). Mature 
caspase 1 is then able to cleave pro-IL-1β and pro-IL-18 into their biologically active 
forms. Interestingly this process is tightly regulated and requires two hits, where the P2X7r 
mediated NLRP3 inflammasome is a secondary signal. First the synthesis of pro-IL-1β and 
NLRP3 is triggered by transcriptional induction via NFκB activated via ligands for Toll 
like receptors (TLRs). Interestingly TLRs have been shown to be involved in the 
pathogenesis of NAFLD (103, 104). A study by Farhadi et al. (105) showed that 
endotoxemia resulting from gut leakage could be a cause for NASH. Many reports after 
have shown the involvement of endotoxin from the gut as a cause for TLR4 activation and 
downstream inflammation (106-110). 
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High mobility group box 1 (HMGB1) is a DAMP widely studied as a transcription 
factor and growth factor, but recently its role as a cytokine mediator of systemic 
inflammation has been identified (111). HMGB1 is released by necrotic or damaged innate 
immune cells such as the macrophages. Interestingly HMGB1 is not released by the 
apoptotic cells (112) indicating a unique role in progressive inflammation. Pyroptosis is a 
unique form of cell death dependent on activation of caspase 1, Pyroptosis leads to rapid 
membrane rupture leading to release of proinflammatory intracellular contents (113, 114).  
In the present study, we used a rodent model of NAFLD fed on high fat diet for 
extended periods of time. Redox stress due to lipotoxicity and innate immune mediation 
serve as a secondary hit. In the NAFLD model we detected higher levels of circulating 
serum HMGB1, in light of the above evidence, we tested the hypothesis that P2X7r 
mediated inflammasome activation along with prevalence of endotoxemia is responsible 
for release of HMGB1 in hepatic macrophages.  Results showed that P2X7r stimulation 
significantly increased levels of extracellular HMGB1 and IL-1β which genetic knockout 
or chemical inactivation of the same reversed the effects. Mechanistically ATP released 
from necrotic hepatocytes could activate P2X7r channels recruiting the NLRP3 
inflammasome. NLRP3 inflammasome was then able to cause membrane pores thereby 
releasing HMGB1. 
3.2 MATERIALS AND METHODS 
Cell culture: Rat immortalized kupffer cell line (Applied Biological Materials Inc., 
Canada) was maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM, 
Corning, VA) supplemented with 10% fetal bovine serum (FBS, Atlas Biologicals, CO) 
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and 1x Penicillin-Streptomycin solution (Gibco, Life Technologies, NY), and grown at 
37°C in a humidified incubator with 5% CO2. HBSS buffer, Tissue culture plastic wares 
were purchased from Corning (Corning, VA). Stock solution of SsnB was prepared in 
dimethyl sulfoxide (DMSO). Before treating the cells with LPS (100ng/ml), cells were 
serum starved (DMEM with 0.25% FBS) overnight followed by treatment with Benzoyl 
ATP as P2X7r Agonist 100 µM (P7 Ag), and 100µM P2X7r Antagonist (A438079) (P7 
An) along with 100 µM (P7 Ag). Control was treated with 0.1% DMSO to remove 
background noise. All treatments were given for 24 hours in 0.25% FBS containing DMEM 
medium 
Mouse Model for NAFLD: Pathogen-free, adult, male mice with C57BL/6J background 
(Jackson Laboratories, Bar Harbor, ME) were used in the study. They were fed with a high-
fat diet (60% kcal fat) (Research diets, New Brunswich, NJ) for 18 weeks and used as a 
model of nonalcoholic fatty liver disease (NAFLD). Mice kept on a similar diet for 4 weeks 
served as a model for early NAFLD (DIO) where mild steatosis was evident with no liver 
inflammation, normal chow diet was used as a model of lean controls. Mice that contained 
deleted purinergic receptor X7 gene (P2X7r KO) (B6.129P2-P2rx7tm1Gab/J) were treated 
like the NAFLD group (supplementary methods). All groups of mice had ad libitum access 
to food and water. All animals were treated in strict accordance with the NIH Guide for the 
Humane Care and Use of Laboratory Animals, and the experiments were approved by the 
institutional review board at the University of South Carolina at Columbia. 
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Laboratory analysis 
Immunohistochemistry: Formalin-fixed, paraffin-embedded intestinal and liver tissue 
from all the mice groups were cut into 5 μm thick tissue sections. Each section was 
deparaffinized (as described in chapter 2). Epitope retrieval of deparaffinized sections was 
carried out using epitope retrieval solution and steamer (IHC-World, Woodstock, - MD) 
following the manufacturer's protocol. The primary antibodies MCP-1, CD-68, IL-1β, 
P2X7r, HMGB1 (Abcam, MA) were used at 1:250 dilutions. Antigen-specific 
immunohistochemistry was performed using Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) following manufacturer's protocols. 3,3' Diaminobenzidine 
(Sigma-Aldrich) was used as a chromogen substrate. Sections were counter-stained by 
Mayer's hematoxylin (Sigma-Aldrich). 
Haematoxylin and Eosin staining: Formalin-fixed tissues were paraffin embedded liver 
tissue sections were stained with Haematoxylin and Eosin by the IRF, University of South 
Carolina, and School of Medicine. 
Immunofluorescence  
In vivo: Formalin-fixed, paraffin embedded tissues sections were subjected to 
deparaffinization using standard instructions. Epitope retrieval of the deparaffinized 
sections was done using epitope retrieval solution and steamer (IHC-World, Woodstock, 
MD) following the manufacturer’s protocol. The primary antibodies anti-NLRP3, anti-
Caspase1, anti ASC2, and Gasdermin D (Santa Cruz biotechnology, Inc., CA and Abcam, 
MA) and used at recommended dilutions. Species-specific anti-IgG secondary antibodies 
conjugated with Alexa Fluor 488 and Alexa Fluor 633 (Invitrogen, California, USA) was 
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used at 1:100 dilution. The sections were mounted in a ProLong gold antifade reagent with 
DAPI (Life technologies, EU, OR). Images were taken under 20x objective using Olympus 
BX51 microscope. 
In vitro: After completion of the treatments under serum starved condition as the 
aforementioned cell culture section, cells attached on coverslips were fixed using 10% 
Neutral Buffer Saline. After washing the cells with PBS, containing 0.1% triton x (Sigma, 
MO) the cells were blocked using 3% BSA, 0.2% Tween (Fisher, NJ), 10% FBS in PBS. 
Cells were incubated with primary antibodies anti-NLRP3, anti-Caspase1, anti ASC2, and 
Gasdermin D, followed by species specific Alexa Fluor 633 and 488 secondary antibodies. 
The stained cells attached on the coverslips were mounted on slides using ProLong gold 
antifade reagent with DAPI (Life technologies, EU, OR) and viewed under 40x oil 
objective using Olympus BX51 microscope. 
Quantitative Real-Time Polymerase Chain Reaction: Gene expression (mRNA) levels 
in the mice liver tissue samples and mouse primary hepatic macrophages were measured 
by real-time reverse transcription-polymerase chain reaction (qRTPCR). Total RNA was 
isolated from liver tissues and mouse primary hepatic macrophages using TRIzol reagent 
(Life Technologies, Carlsbad, CA). Trizol reagent is used to lyse the tissue, RNA extraction 
and purification are carried out by using RNeasy mini kit columns (Qiagen, Valencia, CA) 
following manufacturer’s protocol. 1µg of purified RNA was converted to cDNA by using 
iScript cDNA synthesis kit (Bio-rad, Hercules, CA). Quantitative real-time reverse 
transcription-polymerase chain reaction was performed with the gene specific primers 
using CFX96 thermal cycler (Bio-Rad, Hercules, CA) and SsoAdvanced universal SYBR 
Green supermix (Bio-Rad, Hercules, CA). Threshold Cycle (Ct) values for genes of interest 
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were normalized against 18S (internal control) values in same sample. Reaction was carried 
out in triplicates for each gene and each tissue sample. The relative fold change was 
calculated by the 2-∆∆Ct method.  The primer sequences for mouse and rat targets (Table 
2) 
Western Blotting: In the presence of phosphatase and protease inhibitors (Pierce, 
Rockford, IL), 30 mg of each liver tissue or cells in monolayer was homogenized in 500 
µl of RIPA buffer (Sigma Aldrich) by using dounce homogenizer. The homogenate was 
centrifuged and the supernatant was collected for further experiments. 25 µg of each 
protein sample was loaded on 4–12% bis-tris gradient gel (Invitrogen, California, USA) 
for SDS PAGE. By using precut nitrocellulose/filter paper sandwiches (Bio-Rad 
Laboratories Inc., California, USA) and Trans – Blot Turbo transfer system (Bio-Rad), 
proteins were transferred to nitrocellulose membrane. Blots were blocked with 5% non-fat 
milk solution. Primary antibody against HMGB1, β-actin, IL-1β, Caspase 1 (Abcam, MA) 
were used at recommended dilutions and incubated overnight at 4ºC. Followed by species 
specific secondary antibodies conjugated with HRP (Abcam, MA) for 1h at room 
temperature. Pierce ECL Western Blotting substrate (Thermo Fisher Scientific Inc., 
Rockford, IL) was used. The blot was imaged using G:Box Chemi XX6  (Syngene imaging 
systems) and subjected to densitometry analysis using Image J. 
LDH Cytotoxicity colorimetric assay: Cells were seeded in 96 well cell culture plates 
and treated as described earlier with 0.25% FBS in phenol red free DMEM (Corning, MA), 
after treatment LDH release was measured using the LDH Cytotoxicity colorometric assay 
(Biovision, CA) following manufacturer’s instructions.  
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IL-1β Assay: After cells were treated as described earlier. The supernatant was collected 
and concentrated using a 3kd cutoff filters (Thermo Scientific, MA). Equal volumes of 
concentrated supernatant were used to measure IL-1β by the Quantikine ELISA mouse IL-
1β /IL-1F2 Immunoassay (R&D systems, MN) following manufacturer’s instruction. 
Statistical Analyses: The statistical analysis was performed by analysis of variance 
(ANOVA) which was followed by Bonferroni post-hoc correction for intergroup 
comparisons *p<0.05 and #p<0.01 are considered statistically significant.  
3.3 RESULTS 
P2X7r knockout protects liver tissue against lobular inflammation and steatosis. To 
study the effects of P2X7r on liver injury in a mouse model of NAFLD, C57BL6/J mice 
were fed with high fat diet for 16 weeks. HFD-fed mice showed insulin and leptin 
resistance, macrovesicular steatosis, inflammation and little or no fibrosis, a condition that 
resemble most NAFLD patients. NAFLD mice had markedly increased lobular 
inflammation as shown by hematoxylin eosin staining (Figure 3.1 A) and lipid droplets 
(Figure 3.1 B) when compared to both an early time point with no significant steatosis (4 
weeks of HFD) (DIO group) or lean controls (LC group) (Figure 3.1 C). Interestingly such 
effects were far less pronounced in mice which had a knockout for the P2X7r gene although 
treated like the NAFLD group. NAFLD mice showed significantly increased protein levels 
of P2X7r in the liver with higher immunoreactivity in both hepatocytes and sinusoidal 
spaces when compared to DIO or LC mice (P<0.05) (Figure 3.1 D, Figure 3.1 E), strongly 
suggesting the role of P2X7r in progression of liver injury in NAFLD.  
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Extended consumption of high fat diet leads to hepatic P2X7r activated NLRP3 
inflammasome: There are many recent reports showing the role of NLRP3 inflammasome 
in liver injury in an under lying condition of NAFLD (115-118). Interesting the NLRP3 
inflammasome is assembled by stimulus received from P2X7r ion channels (119-121). To 
study whether high fat diet could lead to inflammasome activation in the mice liver We 
looked at the NLRP3 inflammasome sub-units at gene and protein levels by qRT-PCR and 
Western blots. To show successful assembly of the Inflammasome complex we did co-
localisation studies for NLRP3 with ASC2 and NLRP3 with caspase 1. Results showed 
that there was an increase in gene expression for NLRP3 inflammasome components in the 
NAFLD group compared to the DIO or LC groups and significantly lower in the P2X7r 
KO group (Figure 3.2 A). There was increased co-localisation events for NLRP3 with 
ASC2 and NLRP3 with Caspase 1 especially in the sinusoidal spaces indicating 
inflammasome assembly and activation in the sinusoidal cells of the NAFLD mice, these 
co-localization events were dramatically reduced in the P2X7r KO groups (Figure 3.2 B, 
Figure 3.2 C). Since activated inflammasome leads to cleavage of procaspase 1 to the 
mature caspase 1 we looked at Caspase 1 protein levels, which was significantly lower in 
the P2X7r KO group compared to the NAFLD mice (Figure 3.2 D, Figure 3.2 E). Caspase 
1 is responsible for cleavage of and translocation of Gasdermin D to the membrane forming 
pores (122), Immunofluorescence images show higher immunoreactivity to Gasdermin D 
in the NAFLD group compared to the P2X7r KO group (Figure 3.2 F). Together this data 
suggests that P2X7r mediation is important for NLRP3 inflammasome assembly and 
downstream pyroptosis in the liver of NAFLD mice.  
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P2X7r mediates HMGB1 release from fatty liver in NAFLD: Recent reports have 
shown that pyroptosis is an innate immue function where it could lead to inflammation 
(123, 124), however in metabolic diseases such as NAFLD, this inflammation is unchecked 
and systemic. New reports suggest the role of pyroptosis in damage associated molecular 
pattern, HMGB1 release inducing systemic inflammation in endotoxemia (125, 126). To 
study whether HMGB1 was indeed being released by the liver in NAFLD by P2X7r 
stimulation, we looked at the mRNA and protein levels of HMGB1 in liver tissue and 
serum by qRT-PCR and Western blots. Results showed an increase in mRNA expression 
of HMGB1 in NAFLD liver which was markedly decreased (P<0.05) in the P2X7r KO 
(Figure 3.3 A), this data was further supported by HMGB1 protein levels in the tissue 
(Figure 3.3 B, Figure 3.3 C). Interestingly stable HMGB1 levels were also found in the 
serum (Figure 3.3 D, Figure 3.3 E) in the NAFLD mice, and this was also lowered in P2X7r 
KO mice establishing that P2X7r mediated pyroptosis is responsible for systemic HMGB1 
release. 
P2X7r mediated NLRP3 inflammasome leads to pyroptosis and HMGB1 release in 
Kupffer cells: Innate immune cells such as macrophages, dendritic cells have known to 
release pro-inflammatory cytokines such as IL-1β and various DAMP’s including 
HMGB1. One of the classical features of NLRP3 inflammasome activation is caspase1 
mediated IL-1β release (114). There are many reports of macrophages undergoing 
pyroptosis due to stressed conditions and infection leading to inflammation and DAMP 
release (127-130). To establish macrophages released HMGB1 due to P2X7r mediated 
pyroptosis, we treated the Kupffer cells with LPS an inducer of the NLRP3 subunits as 
well as P2X7r Ag or An. Results showed that there was a significant decrease in the mRNA 
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levels of the different NLRP3 inflammasome subunits ASC-2, NLRP3, Caspase 1 as well 
as downstream effectors IL-1β and IL-18 in the P7 Ag treated cells which were lowered in 
the P7 An treated group. (Figure 3.4 A). We also looked at NLRP3 inflammasome 
formation due to P2X7r stimulation by co-localisation studies of NLRP3 with ASC2 and 
Caspase1. P7 Ag stimulated cells showed higher co-localisation events compared to both 
the control as well the P7 An treated groups (Figure 3.4 B, Figure 3.4 C) Along with 
successful inflammasome activation, Caspase 1 protein levels were higher in the P7 Ag 
groups compared to the control and P7 An treated groups (Figure 3.4 D, Figure 3.4 E). 
Gasdermin D membrane translocation due to P7 Ag was ascertained by co-localising it 
with VEGF-R a membrane receptor; P7 stimulation could recruit more Gasdermin D to the 
membrane (Figure 3.4 F). Pyroptosis was also ascertained by looking at the levels of 
released LDH1 from the P7Ag and An treated cells, the levels of LDH1 increased with 
P2X7r stimulation and was significantly lowered (P<0.05) in cells treated with the P7 
antagonist (Fig 3.4 G).  
P2X7r mediates IL-1β and HMGB1 release in hepatic macrophages in Nonalcoholic 
fatty liver disease: NAFLD is associated with the activation of resident macrophages in 
the liver (57). They mediate their immunological effects by generation of reactive oxygen 
species and release of pro-inflommatory cytokines which play a significant role in the 
inflammation of the liver. We explored the possibility of P2X7r to release IL-1β and 
HMGB1 from activated Kupffer cells by studying immunoreactivity of macrophage 
activation markers CD68 and Monocyte chemoattractant protein (MCP-1) and IL-1β and 
HMGB1 in the fatty liver, our results show that there was tremendous increase in the 
immunoreactivity for CD-68 and MCP-1 in the NAFLD group (Figure 3.5 A, Figure 3.5 
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B) compared to the LC or the DIO group, while much less pronounced in the P2X7r KO 
group. Interestingly immunoreactivity for HMGB1 and IL-1β also was abrogated in the 
P2X7r KO groups (Figure 3.5 C, Figure 3.5 D) eluding to P2X7r as the mediator for 
HMGB1 and IL-1β release in the macrophages. We then looked at HMGB1 and IL-1 β 
production in Kupffer cells in-vitro, interestingly HMGB1 and IL-1 β levels were higher 
in the supernatant of the cells treated with the P7 Ag compared to the Antagonist treated 
cells (Figure 3.5 E, Figure 3.4 F).  
3.4 DISCUSSION: The present study reports a novel mechanistic insight for HMGB1 
release from Kupffer cells via P2X7r mediated NLRP3 inflammasome activated 
pyroptosis. Using a rodent model of steatosis, we show that P2X7r stimulation could 
assemble the NLRP3 inflammasome complex, further we show that this leads to Caspase 
1 activation and membrane pore formation leading to IL-1β maturation and HMGB1 
release. Toll like receptor 4 (TLR4) is activated in different inflammatory conditions. TLR-
4 signaling has been studied extensively in Non-alcoholic fatty liver disease (131-133). In 
NAFLD there is an increase in gut permeability, allowing the leakage of bacterial 
components (103). Portal endotoxemia from gut leaching has been accepted as a source for 
TLR4 ligands in the liver (134, 135). TLR4 signaling leads to NFκB activation leading to 
transcription of NLRP3, Pro-caspase 1 and Pro-IL1β increasing their cytosolic presence 
(136-138). P2X7r mediatated K+ efflux leads to assembly of NLRP3 inflammasome sub-
units, bringing together NLRP3, adaptor protein ASC and pro-caspase 1. ASC binds to 
many subunits of pro-caspase 1 bringing them near one another. Procaspase 1 cleaves each 
other to release active caspase 1. Active caspase 1 is then able to cleave pro-IL-1β and pro-
IL-18 to active IL-1β and IL-18 (120, 139). Caspase 1 also can cleave gasdermin D, leading 
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to its membrane translocation where they polymerize and form membrane pores releasing 
pro-inflammatory cytokines (140). Reports have shown that macrophages are able to 
release HMGB1, a damage associated molecular pattern under conditions of stress (141, 
142). Our data shows that there is an increase in circulating HMGB1 levels in the serum of 
NAFLD mice, using in-vivo and in-vitro studies we have shown that HMGB1 release from 
hepatic macrophages is mediated by the NLRP3 inflammasome formation and is dependent 
on P2X7r stimulation.   
NAFLD mice showed increased lobular inflammation and lipid accumulation 
compared to lean control and an early NAFLD group, interestingly although treated like 
the NAFLD mice, P2X7r KO mice did not show extensive damage as seen in the NAFLD 
mice. Interestingly P2X7r activation increased in the liver tissue with the period of high fat 
diet exposure with lean control mice having little to no P2X7r expression and NAFLD 
group expressing P2X7r in the hepatocytes and the sinusoidal spaces. These results are 
consistent with our previous findings of P2X7r activation in NAFLD/NASH progression 
(24, 30).  
We wished to explore the mechanism of action of P2X7r induced damage in fatty 
liver. P2X7r is known to play a role in inflammation (143) and inflammasome formation 
(134-141). Liver sections from NAFLD mice showed an increase in the mRNA levels of 
the different sub-units of the NLRP3 inflammasome along with successful formation of the 
NLRP3 inflammasome. Along with successful inflammasome assembly we also saw an 
increase in active caspase 1 and gasdermin D expression in the NAFLD mice. Interestingly 
all these effects were completely abrogated in the P2X7r KO mice indicating strong role 
of P2X7r activated NLRP3 inflammasome assembly in NAFLD.  
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Gasdermin D is cleaved by Caspase 1 resulting in its membrane translocation where 
it can form pores releasing pro-inflammatory cytokines such as HMGB1 (140). NAFLD 
mice had high levels of circulating HMGB1 in the serum, this increased presence of serum 
HMGB1 is dependent on the duration of high fat diet and the presence of the P2X7r 
receptor. HMGB1 is a multifunctional protein depending on its location. In the nucleus, it 
distorts the DNA to allow transcription factors to bind to DNA easing transcription, 
extracellularly it acts as a delayed regulator of inflammation released after much later than 
the classical pro-inflammatory markers such as IL-1β, TNF-α, etc. HMGB1 mediates its 
actions in two prominent ways binding to TLR4 a common receptor on immune cells or by 
binding to RAGE, a receptor present in low levels in almost all cells (144, 145). Thus, 
implying that HMGB1 release could indeed lead to systemic inflammation once in 
circulation.  
Since HMGB1 can cause systemic inflammation in chronic metabolic disorders it 
is imperative to find out the mechanisms for its release from the liver in an underlying 
condition of NAFLD. Since macrophages secrete HMGB1 under stress and we observed 
NLRP3 inflammasome assembly in the sinusoidal spaces, we explored the possibility of 
Kupffer cell HMGB1 release mediated by P2X7r activated NLRP3 inflammasome 
formation. NLRP3 inflammasome is mediated by two signals. First TLR-4 receptors are 
activated by bacterial LPS due to portal endotoxemia caused by gut leaching. This leads to 
transcription and cytosolic buildup of NLRP3 inflammasome components and its effectors 
pro-caspase1, pro-IL-1β. In-vitro treatment of Kupffer cells with LPS and P2X7r 
stimulation led to increase in the NLRP3 sub-units, however treatment with both is required 
for NLRP3 inflammasome assembly.  Activated inflammasome leads to release of mature 
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caspase 1. Caspase 1 then leads to Gasdemin D membrane translocation leading to release 
of Lactose dehydrogenase (LDH1) a commonly found cytosolic protein. Interestingly all 
these effects were abolished when the cells were treated with a P2X7r antagonist along 
with LPS and P2X7r agonist, establishing role of P2X7r in NLRP3 inflammasome 
mediated pyroptosis in Kupffer cells.  
Since Kupffer cell activation is a prime inflammatory event in NAFLD, we 
examined the levels of CD68 and MCP-1 (57, 146). Results showed a dramatic increase in 
the levels of MCP-1 and surface expression of CD68 in the sinusoidal cells in the NAFLD 
mice and significantly lower in the P2X7r KO mice. LPS and P2X7r stimulated Kupffer 
cells were also able to release IL-1β and HMGB1 which was blunted using P2X7r 
antagonists. Taken together, our data describes a novel mechanism of HMGB1 release 
mediated by P2X7r activated NLRP3 inflammasome in hepatic macrophages in NAFLD. 
Future studies looking at the effects of the released HMGB1 on distant organs will give us 
a better idea of the systemic effects of NAFLD. Since we also see remediation of 
inflammation by antagonizing the P2X7r channel, future studies looking at P2X7r 
antagonists in remediation of macrophage mediated inflammation in NAFLD may lead to 
interesting therapeutic regimen in NAFLD. 
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Figure 3.1 P2X7r knockout protects liver tissue against lobular inflammation and steatosis. 
A: hematoxylin and eosin-stained paraffin-embedded liver tissue sections of Lean Control 
(LC), Early NAFLD (DIO), NAFLD and P2X7r KO. B: Oil redo stained frozen liver 
sections LC, DIO, NAFLD and P2X7r KO. C. CRN NASH scores for LC, DIO, NAFLD 
and P2X7r KO. D. P2X7r immunoreactivity as shown by immunohistochemistry in liver 
slices from LC, DIO, NAFLD and P2X7r KO mice.  
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Figure 3.2 Extended consumption of high fat diet leads to hepatic P2X7r activated NLRP3 
inflammasome. A: qRT-PCR analysis of mRNA expression of NLRP3, ASC2, IL-18, 
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Caspase 1 and IL-1β, and IL-23 from liver homogenates of LC, DIO, NAFLD and P2X7r 
KO mice, normalized against LC (*P < 0.05). B: Immunofluorescence dual labeling 
depicting NLRP3 (red)-ASC2 (green) colocalization (yellow) in LC, DIO, NAFLD and 
P2X7r KO mouse samples. Images were taken at ×20 magnification. C: 
Immunofluorescence dual labeling depicting NLRP3 (red)-Caspase 1 (green) 
colocalization (yellow) in LC, DIO, NAFLD and P2X7r KO mouse samples. Images were 
taken at ×20 magnification. D. Western blot analysis of Caspase 1 and β-actin protein levels 
from liver homogenates of LC, DIO, NAFLD and P2X7r KO mice. E: Immunoreactive 
band analysis of Caspase 1 normalized against β-actin (*P<0.05). F. Immunofluorescence 
depicting Gasdermin D (red) in LC, DIO, NAFLD and P2X7r KO mouse samples.
 
Figure 3.3 P2X7r mediates HMGB1 release from fatty liver in NAFLD. A. qRT-PCR 
analysis of mRNA expression of HMGB1 from liver homogenates of LC, DIO, NAFLD 
and P2X7r KO mice, normalized against LC (*P < 0.05). B. Western blot analysis of 
HMGB1 protein levels from serum samples of LC, DIO, NAFLD and P2X7r KO mice. C.  
Western blot analysis of HMGB1 and β-actin protein levels from liver homogenates of LC, 
DIO, NAFLD and P2X7r KO mice. D. Morphometric analysis of HMGB1 
immunoreactivity in LC, DIO, NAFLD and P2X7r KO (*P < 0.05)
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Figure 3.4. P2X7r mediated NLRP3 inflammasome leads to pyroptosis and HMGB1 
release in Kupffer cells A: qRT-PCR analysis of mRNA expression of NLRP3, ASC2, IL-
1β, IL-18 from Kupffer cells untreated ctrl, LPS, LPS+P7 Ag (P7Ag) and 
LPS+P7Ag+P7An (P7An) normalized against Ctrl (*P < 0.05). B: Immunofluorescence 
dual labeling depicting NLRP3 (red)-ASC2 (green) colocalization (yellow) in Ctrl, LPS, 
P7 Ag and P7 An treated groups. Images were taken at ×40 magnification. C. 
Immunofluorescence dual labeling depicting NLRP3 (red)-Caspase 1 (green) 
colocalization (yellow) in Ctrl, LPS, P7 Ag and P7 An treated groups. Images were taken 
at ×40 magnification. D. Western blot analysis of Caspase 1 and β-actin protein levels from 
Ctrl, LPS, P7 Ag and P7 An treated groups. E. Morphometric analysis of Caspase 1 
immunoreactivity in Ctrl, LPS, P7 Ag and P7 An treated groups (*P < 0.05). F.  
Immunofluorescence dual labeling depicting Gasdermin D (red)- VEGF-R (green) 
colocalization (yellow) in Ctrl, LPS, P7 Ag and P7 An treated groups. Images were taken 
at ×40 magnification. G. Released LDH levels of Kupffer cells treated with Ctrl, LPS, P7 
Ag and P7 An (*P < 0.05). 
 
Figure 3.5:  P2X7r mediates IL-1β and HMGB1 release in hepatic macrophages in 
Nonalcoholic fatty liver disease.  A. CD-68 immunoreactivity as shown by 
immunohistochemistry in liver slices from LC, DIO, NAFLD and P2X7r KO mice. B. 
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MCP-1 immunoreactivity as shown by immunohistochemistry in liver slices from LC, 
DIO, NAFLD and P2X7r KO mice. C. HMGB1 immunoreactivity as shown by 
immunohistochemistry in liver slices from LC, DIO, NAFLD and P2X7r KO mice. D. IL-
1β immunoreactivity as shown by immunohistochemistry in liver slices from LC, DIO, 
NAFLD and P2X7r KO mice. 
 
Figure 3.5. E: Western blot analysis of HMGB1protein levels from supernatant of Kupffer 
cells treated with Ctrl, LPS, P7 Ag and P7 An. F: IL-1β levels from supernatant of Kupffer 
cells treated with Ctrl, LPS, P7 Ag and P7 An. 
 
Table 3.1: Table showing the primer sequences for the different targets used in this 
study. 
Target Species Sequence 5’-3’ 
HMGB1 F Mus Musculus GGACTCTCCTTTAACCGC 
HMGB1 R Mus Musculus TTGTGATAGCCTTCGCTGGG 
NLRP3 F Mus Musculus GACACGAGTCCTGGTGACTTT 
NLRP3 R Mus Musculus GCCATGGAAGAAAAGTTCCTCTG 
IL-1β F Mus Musculus CCTCGGCCAAGACAGGTCGC 
IL-1β R Mus Musculus TGCCCATCAGAGGCAAGGAGGA 
ASC-2 F Mus Musculus CACTCATTGCCAGGGTCACA 
ASC-2 R Mus Musculus CACGAACTGCCTGGTACTGT 
Caspase 1 F Mus Musculus TGGTCTTGTGACTTGGAGGA 
Caspase 1 R Mus Musculus TGGCTTCTTATTGGCACGAT 
IL-18 F Mus Musculus AGGCCTGACATCTTCTGCAAC 
IL-18 R Mus Musculus CATTGTTCCTGGGCCAAGAGG 
18S F Mus Musculus TTCGAACGTCTGCCCTATCAA 
18S R Mus Musculus ATGGTAGGCACGGCGATA 
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IL-1β F Rattus Norvegicus CCCTGCAGCTGGAGAGTGTGG 
IL-1β R Rattus Norvegicus TGTGCTCTGCTTGAGAGGTGCT 
IL-18 F Rattus Norvegicus ACACCACAAAACCTCAGCCA 
IL-18 R Rattus Norvegicus AGGGACTTGAAACCAGAGCC 
NLRP3 F Rattus Norvegicus GGTGACCTTGTGTGTGCTTG 
NLRP3 R Rattus Norvegicus ATGTCCTGAGCCATGGAAGC 
ASC-2 F Rattus Norvegicus GGACAGTACCAGGCAGTTCG 
ASC-2 R Rattus Norvegicus TTCTTGCAGGTCAGGTTCCA 
18S F Rattus Norvegicus GGATCCATTGGAGGGCAAGT 
18S R Rattus Norvegicus ACGAGCTTTTTAACTGCAGCAA 
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CHAPTER 4 
HMGB1-RAGE PATHWAY DRIVES PEROXYNITRITE SIGNALING 
INDUCED IBD-LIKE INFLAMMATION IN MURINE NON- 
ALCOHOLIC FATTY LIVER DISEASE.3 
 
 
 
                                                          
3Chandrashekaran V, Seth RK, Dattaroy D, Alhasson F, Ziolenka J, Carson J, Berger FG, 
Kalyanaraman B, Diehl AM and Chatterjee S. HMGB1-RAGE pathway drives 
peroxynitrite signaling induced IBD like inflammation in murine Non-alcoholic fatty liver 
disease. Redox Biol. 2017 Oct;13:8-19.. 
Reprinted here with the permission of the publisher. 
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Abstract: 
Recent clinical studies found a strong association of colonic inflammation and 
Inflammatory bowel disease (IBD)-like phenotype with Non Alcoholic Fatty liver Disease 
(NAFLD) yet the mechanisms remain unknown. The present study identifies high mobility 
group box1 (HMGB1) as a key mediator of intestinal inflammation in NAFLD and outlines 
a detailed redox signaling mechanism for such a pathway. NAFLD mice showed liver 
damage and release of elevated HMGB1 in systemic circulation and increased intestinal 
tyrosine nitration that was dependent on NADPH oxidase. Intestines from NAFLD mice 
showed higher Toll like receptor 4 (TLR4) activation and proinflammatory cytokine 
release, an outcome strongly dependent on the existence of NAFLD pathology and 
NADPH oxidase.  Mechanistically intestinal epithelial cells showed the HMGB1 activation 
of TLR-4 was both NADPH oxidase and peroxynitrite dependent with the latter being 
formed by the activation of NADPH oxidase. Proinflammatory cytokine production was 
significantly blocked by the specific peroxynitrite scavenger phenyl boronic acid (FBA), 
AKT inhibition and NADPH oxidase inhibitor Apocynin suggesting NADPH oxidase-
dependent peroxynitrite is a key mediator in TLR-4 activation and cytokine release via an 
AKT dependent pathway. Studies to ascertain the mechanism of HMGB1-mediatied 
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NADPH oxidase activation showed a distinct role of Receptor for advanced glycation end 
products (RAGE) as the use of inhibitors targeted against RAGE or use of deformed 
HMGB1 protein prevented NADPH oxidase activation, peroxynitrite formation, TLR4 
activation and finally cytokine release. Thus, in conclusion the present study identifies a 
novel role of HMGB1 mediated inflammatory pathway that is RAGE and redox signaling 
dependent and helps promote ectopic intestinal inflammation in NAFLD. 
4.1 INTRODUCTION 
Recent clinical reports suggest intestinal inflammation, Inflammatory bowel disease-like 
phenotype (IBD) and neoplasia in NAFLD cases (147-149). These reports are in addition 
to the comorbidities in cardiovascular system associated with fatty liver disease (150). 
Emerging data have highlighted the co-existence of non-alcoholic fatty liver disease 
(NAFLD) and inflammatory bowel disease; both of which are increasingly prevalent 
disorders with significant complications and impact on future health burden (147). With 
colorectal cancer the second leading cause of morbidity and mortality, the clinical finding 
of colonic inflammation and neoplasia in NAFLD is very significant (149, 151). The report 
also finds the association between nonalcoholic steatohepatitis, the active form of NAFLD 
and colorectal neoplasms to be independent of demographics and metabolic factors (149).  
Although reports of a strong intestinal inflammatory phenotype in NAFLD/NASH cases 
and a mutual co-existence of liver inflammation in inflammatory bowel disease exist, the 
cause of such ectopic manifestation remain poorly understood (147).  
NAFLD has been shown to increase circulatory levels of cytokines including 
adipokine leptin in the circulation, with the latter being proinflammatory in nature (57). 
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However, evidence of leptin resistance due to the attenuation of the JAK/STAT signaling 
pathway in peripheral tissues dampen its profound role in the intestine (152, 153). Recent 
reports of other soluble molecular mediators of inflammation in NAFLD have emerged. 
These include several damage associated molecular patterns like HMGB1, uric acid, 
extracellular ATP and NAD and has been found to be prime causes of sterile inflammation 
in the liver and other peripheral organs (104, 154-161).  
NAFLD/ NASH have often been associated with hepatocyte necrosis primarily 
from abnormal triglyceride metabolism and resultant lipotoxicity (162).  Further, there is a 
tight link between JNK1-dependent HMGB1 secretion from lipotoxic hepatocytes and a 
paracrine cytolytic effect on neighboring cholesterol-loaded hepatocytes operating via 
TLR4 (162). Interestingly HMGB1 can bind to TLR4 and generate a similar inflammatory 
response though the binding of lipopolysaccharide is preferred over HMGB1 (163).  
High mobility group box 1 (HMGB1) is a non-histone protein involved in 
maintaining the architecture of chromatin. HMGB1 also acts extracellularly as a cytokine, 
in processes such as inflammation, cell migration and stem cell recruitment. Plasma 
HMGB1 level at admission is an indicator of the severity of illness and a useful mortality 
predictor in exertional heatstroke (164). HMGB1 circulatory levels have been predictors 
of outcome in neuroinflammation, ischemia reperfusion injury and sepsis (156, 165-169). 
We and others have shown that HMGB1 circulatory levels are increased in NASH and are 
found to contribute in the pathology of liver lobule and tubular toxicity (156, 159). 
Though circulatory levels of HMGB1 has been associated with pathology, the 
signaling pathways, its association with pattern recognition receptors in the intestine 
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following liver injury has never been explored. HMGB1 can bind to both TLR4 and RAGE 
and has been extensively reviewed by Weber et. al (163). Their binding abilities depend on 
the redox states of HMGB1 (163). The reduced form contains a thiol group at all three 
cysteine residues with a serum half-life of 17 min. It is this form that can bind to RAGE 
and activate inflammatory pathways (163). The present study tested the hypothesis that 
NAFLD leads to an increase in circulatory HMGB1 levels triggering inflammatory 
pathways in the intestine. Mechanistically HMGB1 binds to RAGE in the distal intestine 
and activates TLR4 translocation to lipid rafts via a peroxynitrite dependent manner. The 
study reports a novel redox-immune crosstalk in a murine model of NAFLD and helps 
understand a possible complicated relationship of innate immune interaction in NAFLD-
induced ectopic intestinal inflammation and IBD-like phenotype. 
 
4.2 MATERIALS AND METHODS 
Animal model 
Mice model for NAFLD  
Pathogen-free, adult, male mice with C57BL/6J background (Jackson Laboratories, Bar 
Harbor, ME) were used in the study. They were fed with a high-fat diet (60% kcal fat) 
(Research diets, New Brunswich, NJ) for 18 wk was used as a model of nonalcoholic fatty 
liver disease (NAFLD). Mice kept on a similar diet for 4 weeks served as a model for early 
NAFLD (DIO), normal chow diet was used as a model of lean controls. Mice that contained 
the disrupted p47 phox (B6.129S2-Ncf1tm1shl N14) (Taconic, Cranbury, NJ) gene were 
treated similar to the NAFLD group. The animals were housed one in each cage before any 
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experimental use. All groups of mice had ad libitum access to food and water and were 
housed in a temperature-controlled room at 23–24°C with a 12-h:12-h light/dark cycle. All 
animals were treated in strict accordance with the NIH Guide for the Humane Care and 
Use of Laboratory Animals, and the experiments were approved by the institutional review 
boards at NIEHS, Duke University, and the University of South Carolina at Columbia. 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded liver and intestine tissue from all the mice groups were 
cut into 5 μm thick tissue sections. Each section was deparaffinized using standard 
protocol. Briefly, sections were incubated with xylene twice for 3 min, washed with 
xylene:ethanol (1:1) for 3 min, and rehydrated through a series of ethanol (twice with 
100%, 95%, 70%, 50%), twice with distilled water, and finally rinsed twice with PBS 
(Sigma-Aldrich). Epitope retrieval of deparaffinized sections was carried out using epitope 
retrieval solution and steamer (IHC-World, Woodstock, - MD) following the 
manufacturer's protocol. The primary antibodies anti-HMGB1 (ab11354), anti-MCP-1 
(ab7202), anti-TGF-β (ab170874), anti-IL1β (ab9722) and anti IFN-γ (ab24979) were 
purchased from Abcam (Cambridge, MA) and used in 1:250 dilutions. Antigen-specific 
immunohistochemistry was performed using Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA) following manufacturer's protocols. 3,3' Diaminobenzidine 
(Sigma-Aldrich) was used as a chromogen substrate. Sections were counter-stained by 
Mayer's hematoxylin (Sigma-Aldrich. Sections were mounted in simpo mount (GBI 
Laboratories, Mukilteo, WA) and observed under a 20X objective. Morphometric analysis 
was done using CellSens Software from Olympus America. 
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Quantitative RT-PCR 
Gene expression levels in tissue samples were measured by two-step qRT-PCR. Total RNA 
was isolated from liver and intestine tissue and cells grown in a monolayer by 
homogenization in TRIzol reagent (Invitrogen) according to the manufacturer's 
instructions and purified with the use of RNeasy mini kit columns (Qiagen, Valencia, CA). 
Purified RNA (1 μg) was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad) 
following the manufacturer's standard protocol. qRT-PCR was performed with the gene-
specific primers using SsoAdvanced SYBR Green supermix (Bio-Rad) and CFX96 thermal 
cycler (Bio-Rad). Threshold Cycle (Ct) values for the selected genes were normalized 
against 18S (internal control) values in the same sample. Each reaction was carried out in 
triplicate for each gene and for each tissue sample. NAFLD mouse liver sample was used 
as the control for comparison with all other liver samples form study groups of mice. The 
relative fold change was calculated by the 2−ΔΔCt method. 
Western Blot 
Tissue (30 mg) from each liver sample was homogenized in 500 μl of RIPA buffer (Sigma-
Aldrich) with protease inhibitor (1X) (Pierce, Rockford, IL) using dounce homogenizer. 
For cells growing in monolayer were harvested using 0.05% Trypsin-EDTA (Gibco) and 
lysed in MPER lysis buffer (100µL) (Thermo-Scientific). The lysate was sonicated using 
the branson ultrasound sonicator. The homogenate was centrifuged and supernatant used 
for SDS PAGE western blotting. 30 µg of protein from each sample was loaded on Novex 
(Invitrogen, Carlsbad, CA) 4–12% bis-tris gradient gel and run for completion of SDS 
PAGE. Resolved proteins bands were transferred to nitrocellulose membrane using precut 
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nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories, Hercules, CA) and Trans-
Blot Turbo transfer system (Bio-Rad) in case of low molecular weight proteins and using 
wet transfer module from Invitrogen in case of high molecular weight proteins. A solution 
of 5% non-fat milk was used for blocking. Primary antibodies against HMGB1, p-AKT 
(ab81283) and Total AKT (ab8805) (all were purchased from Abcam) were used at 1:1000 
dilutions, and compatible horseradish peroxidase-conjugated secondary antibodies were 
used at 1:6000 dilution. Pierce ECL Western Blotting substrate (Thermo Fisher Scientific, 
Rockford, IL) was used as a chemical substrate for the HRP. The blot was imaged using 
G:Box Chemi XX6  (Syngene imaging systems) and subjected to densitometry analysis 
using Image J.  
Cell culture 
Immortalized rat intestinal epithelial cells (IEC-6) were purchased from ATCC (CRL-
1592) was maintained in high glucose Dulbelcos modified eagles medium (DMEM), 
Corning (Tewksbury, MA) supplemented with 10% fetal bovine serum (FBS), Atlanta 
biologicals (Norcross, GA) supplemented with 2mM glutamine, 0.1 U/ml Insulin, 100U/ml 
Penicillin, and 100μg/ml streptomycin; Gibco (Grand Island, NY) at 37oC in a humidified 
atmosphere of 5% CO2.  The cells were then treated with recombinant rat HMGB1 
(Mybiosource. San Diego, CA) 30ng/ml a cytokine mediator of inflammation released by 
activated macrophages able to bind to ad activate RAGE & TLR4, Apocynin (Sigma-
Aldrich) 100µM an inhibitor of NADPH oxidase activity and thus prevents production of 
superoxide, RAGE antagonist (FPS-ZM1, Milipore, MA) 200 nM V-domain ligand 
binding RAGE inhibitor, Peroxynitrite (Cayman Chem, Ann Arbor, MI) 300 µM a highly 
reactive structural isomer of nitrate, , Phenyl Boronic Acid (FBA) (Sigma Aldrich) 100µM 
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was used as a scavenger for Peroxynitrite, PI3K inhibitor (LY294002, Sigma Aldrich) 
10µM as an inhibitor for AKT phosphorylation as required either separately or in 
combinations. To study the role of HMGB1, HMGB1 was denatured by boiling it at 100oC 
for 1h. All treatments were carried for a period of 48h before further processing. 
Immunofluorescence 
Treated and control IEC-6 cells were fixed in 10% Neutral buffered Formalin for 15 min 
at room temperature (RT). They were then permeabilized in PBS with 0.1% Triton X 
(PBSTx) for 10 min followed by blocking with PBS containing  10% fetal bovine serum, 
3%  bovine serum albumin and 0.2% Tween 20 for 1h, Tissues were deparaffinized as 
described earlier followed by epitope retrieval. The tissues were blocked with 3% BSA and 
0.05% Tween 20 for 1h followed by incubation in IHC-Tek Antibody diluent solution. 
Tissues and cells were then incubated with primary antibodies P47-Phox (SantaCruz SC-
17845), GP-91 Phox (SantaCruz SC-5827) and 3-Nitro Tyrosine (Abcam ab110282), TLR-
4 (Abcam ab13556), Flotilin (SantaCruz SC-74566) (1:250) diluted in blocking buffer at 
4˚C overnight. Cells were washed thrice in PBSTx for 10 min each. The cells and tissues 
were then incubated with compatible AlexaFlour conjugated secondary antibodies (1:100) 
from Invitrogen. (Grand Island, NY), followed by three washes in PBSTx for 10 min each. 
Finally, the cells were mounted in Prolong gold antifade reagent with DAPI. Images were 
taken under 40X and 60X objective using the Olympus BX51 microscope. 
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Statistical analysis 
All experiments were repeated three times with 3 mice per group (N = 3; data from each 
group of mice was pooled). The statistical analysis was carried out by analysis of variance 
(ANOVA) followed by the Bonferroni posthoc correction for intergroup comparisons. 
Quantitative data from western blots as depicted by the relative intensity of the bands were 
analyzed by performing a student’s t test.  
4.3 RESULTS:  
Increased circulatory HMGB1 in NAFLD correlates well with peroxynitrite 
generation, TLR4 trafficking to lipid rafts and intestinal inflammation in a NOX2 
dependent manner. To study the role of circulatory HMGB1 in NAFLD in intestinal 
inflammation, mouse intestinal tissue was evaluated for the mechanism of ectopic 
inflammation. Results showed that there was a significant increase in the levels of MCP-1, 
TGF-β, IL1β and IFN-γ when assessed by immunohistochemistry in the NAFLD group 
when compared to both LC and DIO groups (Figure. 4.1 A). Further, mRNA levels of the 
above cytokines increased significantly (p<0.001) in NAFLD group when compared to 
both LC and DIO groups respectively suggesting the endogenous nature of the 
inflammation (Figure. 4.1 B). Both increased levels of mRNA and protein of the cytokines 
were significantly decreased (p<0.001) in p47 phox knockout mice when compared to 
NAFLD mice suggesting that the inflammation was NOX-2 dependent (Figure. 4.1 A and 
4. 1 B). To study whether NOX2 was activated in the small intestine, experiments were 
performed to assess the membrane assembly of the NOX2 subunits p47 phox and gp91 
phox using immunofluorescence microscopy and co-localisation studies. Results suggested 
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that the number of colocalization events of gp91 phox and p47 phox in the intestinal 
membrane were significantly higher in NAFLD group when compared to both LC and DIO 
groups (Figure. 4.1 C and Figure. 4.1 D) while deletion of the p47 phox gene caused a 
significant decrease in the membrane assembly (Figure. 4.1 C and Figure. 4.1 D) 
suggesting a strong NOX2 activation in the NAFLD intestine. Since we have shown the 
role of NOX2 in peroxynitrite formation in NAFLD, studies were conducted to show the 
levels of 3-nitrotyrosine in the NAFLD intestine and whether the tyrosine nitration by 
peroxynitrite was NOX-2 dependent. Results showed that there was a significant increase 
in 3-nitrotyrosine levels in the NAFLD intestine group when compared to both LC and 
DIO groups (Figure, 4.1 E and Figure. 4.1 F). 3-nitrotyrosine levels were significantly 
decreased in the P47 phox knockout mice suggesting that the tyrosine nitration from 
primarily peroxynitrite generation was NOX-2 dependent though other non-peroxynitrite 
sources of 3-nitrotyrosine generation cannot be ruled out at this point (Figure. 4.1 E and 
Figure 4.1 F). We have shown previously that NOX-2 drives TLR4 trafficking into the 
lipid rafts (36). To study the role of NOX2 in TLR4 trafficking to lipid rafts and confirming 
the role of NOX2-mediated TLR4 pathway in inflammation of the intestine, TLR4-Flotillin 
colocalization were assessed in the NAFLD intestines. Results showed that the number of 
TLR4-Flotillin colocalizations were significantly increased in the NAFLD intestines when 
compared to both LC and DIO tissues (Figure. 4.1 G and Figure. 4.1 H) while there was a 
significant decrease in the above colocalization events in the p47 phox knock mice 
intestines suggesting a NOX-2 derived TLR4 trafficking (Figure. 4.1 G and Figure. 4.1 H). 
NAFLD group also showed higher Claudin-2 protein levels, a hallmark of IBD-like 
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phenotype when compared to lean and DIO groups (Figure. 4.1 I). P47 phox deletion 
reversed the changes observed in Claudin-2 levels (Fig. 4.1 I). 
HMGB1 primes NOX2 activation and TLR4-derived inflammation in intestinal 
epithelial cells. To study the mechanism of HMGB1 induced NOX2 activation and 
subsequent inflammation in the intestine, experiments were performed in intestinal 
epithelial cells (IEC6). Results showed that cells primed with HMGB1 showed a significant 
increase in p47 phox-gp91 colocalization events when compared to vehicle control (Fig. 
4.2 A, Figure 4.2 B). HMGB1 primed cells treated with apocynin had significantly 
decreased colocalization events when compared to HMGB1-only treatment (Figure. 4.2 A, 
Figure. 4.2 B). HMGB1-primed cells had significantly higher immunoreactivity of tyrosine 
nitration indicating a possible role of peroxynitrite that is NOX2 dependent when compared 
to vehicle control and cells treated with apocynin (Figure. 4.2 C, Figure. 4.2 D). To confirm 
the role of HMGB1 in NOX2 driven TLR4 trafficking, HMGB1 primed cells were assessed 
for TLR4-Flotillin colocalization using immunofluorescence microscopy. Results showed 
that HMGB1-primed cells had significant increase in TLR4-Flotillin colocalization events 
when compared to vehicle control and apocynin treatment (Figure. 4.2 E, Figure 4.2 F). 
The results suggested that HMGB1-mediated NOX2 was involved in TLR4 trafficking into 
the lipid rafts, a crucial event that drives intestinal inflammation in NAFLD. TLR4 
activation leads to an increase in the release of interleukins 1β and 6, that have been found 
to have profound roles in intestinal inflammation and IBD-like phenotype (170). To study 
whether HMGB1-activated NOX2 was involved in the release of IL1β and IL6, mRNA 
expressions of these cytokines were assessed from cell lysates primed with HMGB1. 
Results showed that HMGB1-primed cells had significantly increased IL1β and IL6 
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mRNA expression when compared to vehicle control (p<0.001) and HMGB1-primed cells 
treated with Apocynin (p<0.001) (Figure. 4.2 G and 4.2 H). The results suggested that 
HMGB1-induced NOX2 activation increases expression of TLR4-pathway cytokines IL1β 
and IL6. 
Peroxynitrite drives TLR4 trafficking into lipid rafts via the AKT pathway. Results 
obtained both invivo and invitro (Figure 4.1-4.2) suggested a possible role for NOX2 
derived peroxynitrite in TLR4 activation and release of IL1β and IL6. To study the 
involvement of peroxynitrite and its activation of AKT pathway for TLR4-trafficking into 
the lipid rafts, experiments were designed in vitro to confirm this mechanism. Results 
showed that cells primed with peroxynitrite caused a significant increase in TLR4-Flotillin 
colocalization events when compared to vehicle control (Figure. 4.3 A, Figure. 4.3 B). 
Cells primed with peroxynitrite but treated with specific peroxynitrite scavenger phenyl 
boronic acid (FBA) showed a significant decrease in TLR4-Flotillin colocalization events 
when compared to peroxynitrite-only primed cells (Figure. 4.3 A, Figure. 4.3 B). To show 
the role of AKT in peroxynitrite-induced TLR4 trafficking into lipid rafts, cells were 
treated with PI3K inhibitor. Results showed that peroxynitrite primed cells and PI3K 
inhibitor showed a significant decrease in TLR4 trafficking into lipid rafts as indicated by 
decreased TLR4-Flotillin colocalization events (Figure. 4.3 A, Figure. 4.3 B). To show that 
peroxynitrite caused AKT phosphorylation in IE6 cells, experiments were performed to 
study the phosphorylation in AKT and was compared to total AKT levels in the cell lysate. 
Results showed that AKT phosphorylation peaked at 40 minutes post priming with 
peroxynitrite (Figure. 4.3 C; Figure. 4.3 D). Thus, results from Figures. 4.3 A and 4.3 C 
suggested a strong role of peroxynitrite-induced AKT phosphorylation in TLR4 activation 
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a key event in IE6 cells. To study whether peroxynitrite-induced AKT phosphorylation and 
TL4 activation was involved in the proinflammatory phenotype in intestinal epithelial cells, 
mRNA expression of IL1β and IL6 were observed. Results showed that mRNA expression 
of IL1β and IL6 were increased significantly (p<0.001) in peroxynitrite primed IE6 cells 
when compared to vehicle controls (Figure. 4.3 E and Figure. 4.3 F). Cell treated with 
peroxynitrite scavenger FBA or AKT inhibitor had significantly decreased (p<0.001) 
expressions of IL1β and IL6 when compared to peroxynitrite-only group (Figure. 4.3 E and 
Figure. 4.3 F). 
HMGB1 binding to RAGE causes NOX2 activation and peroxynitrite generation. To 
study the levels of RAGE in NAFLD intestines, qRTPCR was conducted from tissue 
lysates. Results showed that NAFLD intestines showed a 35-fold increase in RAGE mRNA 
expression when compared to lean controls (Figure. 4.4 A) and a >2-fold increase when 
compared to DIO group (which does not show liver disease based on NASH scores). 
Intestinal epithelial cells showed a significant increase in P47Phox expression (>5 fold) 
when primed with HMGB1 but had significantly decreased P47Phox expression following 
incubation with a specific RAGE-antagonist (Figure. 4.4 B). IE6 cells primed with 
HMGB1 showed significantly increased gp91phox-p47 phox colocalization suggesting a 
strong NOX2 activation when compared to vehicle controls (Figure. 4.4 C and Figure. 4.4 
D). To ensure the specificity of HMGB1-RAGE binding we denatured the HMGB1 by 
boiling the protein for 60 minutes. Also, we used a specific antagonist of RAGE as a dual 
approach. Results showed that NOX2 activation was significantly inhibited using RAGE 
antagonist and denatured HMGB1 as shown by decreased gp91-p47 phox colocalization 
events (Figure. 4.4 C and Figure. 4.4 D). Tyrosine nitration which is a possible result from 
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peroxynitrite dependent redox pathway was significantly increased in HMGB1-primed 
cells when compared to vehicle controls (Figure. 4.4 E and Figure. 4.4 F). Incubation with 
either a specific RAGE antagonist or use of denatured HMGB1 significantly decreased 
tyrosine nitration when compared to HMGB1 primed cells (Figure. 4.4 E and Figure. 4.4 
F) suggesting that HMGB1-RAGE binding was responsible for NOX2 activation and 
peroxynitrite generation. 
HMGB1 binding to RAGE causes TLR4 activation and proinflammatory cytokine 
release. Following the results of HMGB1-RAGE activation of NOX2 and peroxynitrite 
generation, it was imperative that we study the above pathway for TLR4 activation and 
proinflammatory events in the intestinal cells. Results showed that HMGB1 primed cells 
showed significant increase in TLR4-Flotillin colocalization that was blunted in the 
presence of a specific RAGE antagonist and use of denatured HMGB1 (Figure. 4.5 A and 
Figure. 4.5 B). Use of RAGE antagonist blunted TLR4 flotillin colocalization also implied 
that HMGB1-binding to TLR4 was not a predominant pathway in the IE6 cells (Figure. 4.5 
A). The significant (p<0.001) increase in IL1β and IL6 mRNA expression by IE6 cells 
following HMGB1 priming was significantly decreased (p<0.001) using specific 
antagonist against RAGE and the use of denatured HMGB1 suggesting that HMGB1-
RAGE binding was instrumental in proinflammatory cytokine expression (Figure. 4.5 C 
and Figure. 4.5 D). Since monocyte chemoattractant protein (MCP1) also plays a role in 
an inflammatory microenvironment, mRNA expression analysis of MCP1 was assayed in 
IE6 cells. Results showed that MCP1 expression was significantly increased (p<0.001) 
following HMGB1 priming (>40 fold) when compared to vehicle controls (Figure. 4.5 E). 
Use of an antagonist for RAGE or use of denatured HMGB1 which has lost its binding 
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ability to RAGE significantly (p<0.001) decreased expression of MCP1 mRNA suggesting 
that HMGB1-RAGE interaction increased possibility of a proinflammatory 
microenvironment (Figure. 4.5 E). 
4.4 DISCUSSION: 
We present a novel pathological pathway of ectopic inflammation in the intestine following 
development of progressive NAFLD that is mediated by a) circulatory HMGB1-RAGE 
interaction and b) NOX2-Peroxynitrite-mediated TLR4 activation. The HMGB1-RAGE-
mediated NOX2 activation and subsequent peroxynitrite induced TLR4 trafficking into the 
lipid rafts caused higher expression of IL1β and IL6 followed by increased release of MCP-
1, a chemokine known to attract neutrophils. 
NAFLD and its progressive inflammatory phase nonalcoholic steatohepatitis has 
been associated with intestinal inflammation resembling an IBD phenotype and colonic 
neoplasia (149). Interestingly, steatosis or benign fat deposition in the liver was not found 
to be associated with neoplasia (149). Our results where DIO group represented a benign 
steatosis group showed no intestinal inflammation or cytokine release thus conforming to 
the clinical data. This event may be ascribed to less HMGB1 in the liver and subsequent 
decreased circulatory HMGB1 levels following decreased liver cell necrosis. Thus, a 
progressive NAFLD with lobular inflammation as seen in our results paves way for higher 
circulatory HMGB1 and is a ligand for a series of proinflammatory events in the intestinal 
epithelial cells. The results also link the strong inflammatory phenotype observed in 
NAFLD intestines in our studies. 
Though a strong association was observed in patients with NAFLD/NASH to 
development of colonic inflammation or studies that found NAFLD associations with IBD 
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phenotype, the mechanisms that link these two inflammatory events were unclear (147, 
149). Interestingly, there are considerable reports of circulatory cytokines, lack of 
adiponectin or increased leptin in NAFLD that are proinflammatory in nature but a direct 
mechanistic link to colonic inflammation is scarce (171). Our observation that high 
circulatory HMGB1 in absence of significant other organ injuries probably originates in 
the damaged liver bodes well for a prominent role of this DAMP in causing ectopic 
intestinal inflammation. DAMPS has been found to play a prominent role in inflammation 
in many diseases (172). However caution should be exercised when interpreting the data 
since prolonged feeding with high fat diet has been associated with inflammatory lesions 
in the intestine (173). Further the present study is limited in specifying the role of 
circulatory HMGB1 in causing ectopic inflammation in the intestine since we have 
unpublished data where intestinal HMGB1 was markedly increased following high fat 
feeding though it was significantly less than the circulatory levels of HMGB1. Future 
studies would have to focus on generating models that would clearly illustrate the source 
of HMGB1. Sterile inflammation in the liver is found to be associated with HMGB1 and 
other DAMPs (174). The above fact is supported by our results that show liver HMGB1 
levels are significantly high in NAFLD and little or no HMGB1 protein levels were 
detectable in the heart or kidney in our model of high fat fed mouse model of NAFLD. 
HMGB1 is known for its proinflamamtory role in the intestine and other tissues including 
liver (155, 174, 175). High circulatory levels of HMGB1 was associated with increased 
expression of proinflammatory mediators IL1β, MCP1, TGF-β and IFN-γ (156, 176). High 
HMGB1 was also associated with NOX2 activation and increased 3-nitro tyrosine 
formation, a marker of peroxynitrite-mediated nitrative stress (177-179). The above events 
83 
 
decreased significantly in p47 phox knockout mice. Peroxynitrite formation and TLR4 
trafficking to the lipid rafts also decreased in P47 phox knockout mice thus indicating that 
the proinflammatory events including TLR4 trafficking was dependent on NOX2. This was 
intriguing since HMGB1 is known to bind TLR4 in generating a proinflammatory cascade. 
Our results also implied that if HMGB1 and redox signaling events were to generate an 
inflammatory phenotype in the intestine, it had to do so by activating NOX2. Studies 
suggest that HMGB1 can induce an activation of NOX2 by a Mac-1 dependent pathway 
but in contrast can also induce phosphorylation of p40 subunit of NOX2, thereby inhibiting 
its activation through a RAGE dependent pathway in neutrophils (38, 177). With HMGB1 
levels being associated with increased NOX2 activation in the intestine we resorted to study 
the redox pathway of inducing TLR4 signaling in our studies. Results showed that 
HMGB1-primed intestinal epithelial cells activated NOX2, formed higher nitration of 
tyrosine residues, increased TLR4 trafficking into lipid rafts and caused higher expression 
of proinflammatory cytokines IL1β and IL6, events that were blocked by use of NOX2 
inhibitor apocynin. Thus, HMGB1-NOX2 activation was upstream to TLR4 activation and 
the results opened the possibility of a non-TLR4 based mechanism in our studies. Use of 
AKT inhibitor also blocked peroxynitrite mediated TLR4 trafficking suggesting NOX2-
peroxynitrite-AKT signaling as a primary pathway for TLR4-mediated inflammation in the 
intestinal epithelial cells.  
RAGE has been found to bind HMGB1 in the B box binding region (163). The 
three redox states of HMGB1 differ by structure, half-life, and activity. The redox states 
determine the stability of HMGB1 and its binding to either RAGE or TLR4 (163). We 
found higher RAGE expression in the NAFLD intestines. Our results also showed 
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decreased NOX2 activation, peroxynitrite formation, TLR4 trafficking and 
proinflammatory mediator expression in RAGE antagonist treated HMGB1 primed 
intestinal epithelial cells suggesting strongly that HMGB1 mediates its effect through 
RAGE binding. Further the decreased and almost negligible TLR4 trafficking in the 
presence of RAGE antagonist proved that HMGB1-RAGE binding but not HMGB1-TLR4 
caused the inflammatory events in the cells. HMGB1 mediated effects were further 
confirmed using denatured HMGB1 primed cells.  
Though our results support strongly the involvement of circulatory HMGB1-
mediated inflammation in the NAFLD intestine, several questions remain unanswered. 
Firstly, a high fat diet induced NAFLD model that we have used in the present study is a 
slow and progressive inducer of liver disease pathology (38). Such models cause obesity 
and insulin resistance and has been shown to alter gut microbiome and dysbiosis. It is 
shown in clinical studies that dysbiosis is associated with IBD like phenotype which can 
cause liver disease by itself (147, 171). This fact complicates our interpretation that 
HMGB1 was primarily derived from liver and did not originate from the intestine. Most 
murine models of NAFLD cause gut dysbiosis and there is hardly a way that a liver disease 
phenotype is established where the intestine is unaffected. Secondly, HMGB1-TLR4 
pathway is favored because of the increased stability of HMGB1 (163). This event does 
not rule out the HMGB1-TLR4-mediated inflammation in other cell types of the intestine 
since we studied the pathways only in the intestinal epithelial cells. 
Taken together, our data in both an in vivo and in vitro setting shows a novel 
HMGB1-RAGE mediated redox signaling pathway that exerts its effect through 
peroxynitrite induced AKT phosphorylation which in turn directs TLR4 to lipid rafts (Fig. 
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7). The ensuing event caused uninterrupted inflammation through release of IL1β, IL6 and 
MCP1 and resulted in an IBD-like phenotype. With recent published studies including ours 
showing the efficacy of specific peroxynitrite scavenger phenyl boronic acid (FBA) in 
curbing NAFLD mediated inflammation, it will be justified to assume that FBA may be a 
likely candidate for an interventional strategy to curb ectopic inflammatory events in 
NAFLD or IBD itself (36). The present study also finds a probable mechanistic link to 
NAFLD induced intestinal neoplasia since chronic inflammation such as that in NAFLD 
is deemed to be paramount to such an event in humans. 
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Figure 4.1. Increased circulatory HMGB1 in NAFLD correlates well with peroxynitrite 
generation, TLR4 trafficking to lipid rafts and intestinal inflammation in a NOX2 
dependent manner. A: Representative images of MCP-1, TGF-β, IL-1β and IFNγ 
immunoreactivity as shown by immunohistochemistry in the intestinal sections of Lean 
Control (LC), Early NAFLD (DIO), NAFLD and P47Phox KO mice taken at ×20 
magnification. (*P < 0.05). B: qRT-PCR analysis of mRNA expression of MCP-1, TGF-
β, IL-1β and IFN-γ from intestines of Lean Control (LC), Early NAFLD (DIO), NAFLD 
and P47Phox KO mice. (*P < 0.05) 
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Figure 4.1 C: Representative images for p47Phox (green) co-localisation with GP-91 Phox 
(Red) as shown by immunofluorescence microscopy in the intestinal sections of Lean 
Control (LC), Early NAFLD (DIO), NAFLD and P47Phox KO mice taken at 20x 
magnification. (*P < 0.05). D: Morphometric analysis of p47Phox-GP-91Phox co-
localisation (mean data from three separate microscopic fields were plotted on Y-axis) in 
Lean Control (LC), Early NAFLD (DIO), NAFLD and p47Phox KO mice. E: 
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Representative images of 3 Nitro-tyrosine immunoreactivity as shown by 
immunofluorescence microscopy in the intestinal sections of (LC), (DIO), NAFLD and 
P47Phox KO mice taken at 20x magnification. (*P < 0.05). F: Morphometric analysis of 
3-Nitro-tyrosine immunofluorescence (mean data from three separate microscopic fields 
were plotted on Y-axis) in LC, DIO, NAFLD and p47Phox KO mice. G: Representative 
images for Flotilin (green) co-localisation with TLR-4 (Red) as shown by 
immunofluorescence microscopy in the intestinal sections of (LC), (DIO), NAFLD and 
P47Phox KO mice taken at ×20 magnification. (*P < 0.05). H: Morphometric analysis of 
TLR-4-Flotilin co-localisation (mean data from three separate microscopic fields were 
plotted on Y-axis) in LC, DIO, NAFLD and p47Phox KO mice. I: Representative images 
of Claudin 2 immunoreactivity as shown by immunofluorescence microscopy in the 
intestinal sections of (LC), (DIO), NAFLD and P47Phox KO mice taken at 20x 
magnification. (*P < 0.05). 
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Figure 4.2: HMGB1 primes NOX2 activation and TLR4-derived inflammation in intestinal 
epithelial cells. A: Representative images for p47Phox (green) co-localisation with GP-91 
Phox (Red) as shown by immunofluorescence microscopy in the intestinal epithelial cells 
(IEC-6) treated with no treatment (Ctrl), HMGB1 or HMGB1 with NADPH oxidase 
inhibitor Apocynin (HMGB1+Apo) at 40x magnification. (*P < 0.05). B: Morphometric 
analysis of p47Phox-GP-91Phox co-localisation (mean data from three separate 
microscopic fields were plotted on Y-axis) in IEC-6 cells untreated control or treated with 
HMGB1 and HMGB1+Apocynin (HMGB1+Apo). C: Representative images of 3 Nitro-
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tyrosine immunoreactivity as shown by immunofluorescence microscopy in IEC-6 cells 
treated with Ctrl, HMGB1 or HMGB1+Apo at 40x magnification. (*P < 0.05). D: 
Morphometric analysis of 3-Nitro-tyrosine immunofluorescence (mean data from three 
separate microscopic fields were plotted on Y-axis) in in IEC-6 cells untreated control or 
treated with HMGB1 and HMGB1+Apo. E: Representative images for Flotilin (green) co-
localisation with TLR-4 (Red) as shown by immunofluorescence microscopy IEC-6 cells 
treated with Ctrl, HMGB1 or HMGB1+Apo at 40x magnification. (*P < 0.05). F: 
Morphometric analysis of TLR-4-Flotilin co-localisation (mean data from three separate 
microscopic fields were plotted on Y-axis) in in IEC-6 cells untreated control or treated 
with HMGB1 and HMGB1+Apo. 
      
Figure 4.2 qRT-PCR analysis of mRNA expression of G: IL-1β and H:.IL-6 from IEC-6 
cells treated with Ctrl, HMGB1 or HMGB1+Apo. 
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Figure 4.3 Peroxynitrite drives TLR4 trafficking into lipid rafts via the AKT pathway.  A: 
Representative images for Flotilin (green) co-localisation with TLR-4 (Red) as shown by 
immunofluorescence microscopy IEC-6 cells treated with no treatment (Ctrl), Peroxynitrite 
(Peroxy), Peroxynitrite+Phenyl boronic acid (Peroxy+FBA) or Peroxynitrite+AKT 
inhibitor (Peroxy+AKTi) (*P < 0.05). B: Morphometric analysis of TLR-4-Flotilin co-
localisation (mean data from three separate microscopic fields were plotted on Y-axis) in 
IEC-6 cells untreated control or treated with Peroxynitrite (Peroxy), 
Peroxynitrite+Phenylboronic acid (Peroxy+FBA) and Peroxynitrite +AKT inhibitor 
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(Peroxy+AKTi). C: Western blot analysis of p-AKT and Total AKT protein levels of IEC-
6 cells, Ctrl, Peroxy and Peroxy+FBA at 20 m time intervals (*P < 0.05). D:  Morphometric 
analysis of p-AKT immunoreactivity in IEC-6 cells untreated control or treated with 
Peroxy and Peroxy+FBA for 20 min intervals. E: qRT-PCR analysis of mRNA expression 
of IL-1β and F: IL-6 from IEC-6 cells treated with Ctrl, Peroxy and Peroxy+FBA and 
Peroxy+AKTi (*P < 0.05). 
 
Figure 4.4 HMGB1 binding to RAGE causes NOX2 activation and peroxynitrite 
generation.  A: qRT-PCR analysis of mRNA expression of RAGE from intestines of Lean 
Control (LC), Early NAFLD (DIO), NAFLD mice. B: qRT-PCR analysis of mRNA 
expression of p47Phox from IEC-6 cells treated with Ctrl, HMGB1 or HMGB1+RAGE 
Antagonist (HMGB1+RAGE An). C: Representative images for p47Phox (green) co-
localisation with GP-91 Phox (Red) as shown by immunofluorescence microscopy in the 
intestinal epithelial cells (IEC-6) treated with no treatment (Ctrl), HMGB1 or 
HMGB1+RAGE An and HMGB1 destroyed (des) at 40x magnification. (*P < 0.05). D: 
Morphometric analysis of p47Phox-GP-91Phox co-localisation (mean data from three 
separate microscopic fields were plotted on Y-axis) in IEC-6 cells untreated control or 
treated with HMGB1, HMGB1+RAGE An and HMGB1 des. 
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Figure 4.4 E: Representative images of 3 Nitro-tyrosine immunoreactivity as shown by 
immunofluorescence microscopy in IEC-6 cells treated with Ctrl, HMGB1 or 
HMGB1+RAGE An and HMGB1 des at 40x magnification. (*P < 0.05). F: Morphometric 
analysis of 3-Nitro-tyrosine immunofluorescence (mean data from three separate 
microscopic fields were plotted on Y-axis) in in IEC-6 cells untreated control or treated 
with HMGB1, HMGB1+RAGE An and HMGB1 des. 
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Figure 4.5. HMGB1 binding to RAGE causes TLR4 activation and proinflammatory 
cytokine release.  A: Representative images for Flotilin (green) co-localisation with TLR-
4 (Red) as shown by immunofluorescence microscopy IEC-6 cells treated with no 
treatment (Ctrl), HMGB1, HMGB1+RAGE Antagonist (HMGB1+RAGE An) or 
destroyed HMGB1 (HMGB1 des) (*P < 0.05). B: Morphometric analysis of TLR-4-
Flotilin co-localisation (mean data from three separate microscopic fields were plotted on 
Y-axis) in IEC-6 cells untreated control or treated with HMGB1, HMGB1+RAGE An and 
HMGB1 des. C: qRT-PCR analysis of mRNA expression of IL-1β, D: IL-6 and E: MCP-
1 from IEC-6 cells treated with Ctrl, HMGB1, HMGB1+RAGE An and HMGB1 des. (*P 
<0.05).  
 
Figure 4.6: A pictorial representation of the molecular process in liver HMGB-1-RAGE 
mediated ectopic intestinal inflammation in murine NAFLD.  
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Table 4.1: Table showing the primer sequences for the different targets used in this study. 
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CHAPTER 5 
CONCLUSION 
Obesity has slowly become the public health problem of this century. More than two-thirds 
of the adult American population is considered obese. Obesity is a complex disorder which 
increases the chances of various physical diseases. Obesity is associated with a lot of 
inflammatory metabolic disorders such as Non-alcoholic fatty liver disease (NAFLD). 
NAFLD is a hepatic manifestation of metabolic syndrome which arises due to abnormal 
fat (<5% of the liver weight) accumulation in liver. According to the widely recognized 
“multiple hits” theory of NASH, the first hit due to accumulation of lipids in the liver make 
it susceptible to secondary insults like oxidative stress, subsequent lipid peroxidation, 
proinflamatory cytokines, adipokines and mitochondrial dysfunction. All these factors lead 
to hepatic injury leading to inflammation and fibrosis which if unchecked can lead to liver 
cirrhosis or hepatocellular cancer. The greatest problem with this disease is that it is largely 
asymptomatic and the affected individuals feel normal and go undetected until the liver 
undergoes tissue hardening and scarring.  Previous studies from our group has shown that 
chronic exposure to low doses of Bromo-dichloromethane (BDCM), a common water 
disinfection byproduct is able to aggravate liver injury causing Non-alcoholic 
steatohepatitis (NASH) where CYP2E1 mediated oxidative stress acts as the secondary hit 
in obese mice. In the present study, I studied the molecular mechanisms by which Hepatic 
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stellate cells, a group of fibroblastic liver cells can get activated in an underlying condition 
of NASH induced by BDCM exposure, I also looked at how obesity is able to cause 
systemic inflammation by release of pro-inflammatory mediators via pyroptosis from the 
liver resident macrophage cells in-vivo and in-vitro models of NAFLD.
There are many reports of Hepatic stellate cell activation in the progression of 
NAFLD/NASH (180-182), however the exact mechanism of the process is largely unclear. 
Here, I investigated the role of Leptin mediated P2X7r stimulation leading to glucose 
uptake via GLUT4 induction activating hepatic stellate cells (HSC’s) during NASH. 
Human NASH liver samples and a high-fat (60% kcal) diet-fed BDCM induced mouse 
NASH model were used for this study. Mice deficient in genes for leptin, and P2X7r were 
used to prove the role of the leptin-P2X7r-GLUT4 axis. Our results showed that Leptin 
was essential for significant activation of P2X7r channels wild-type (C57BL/6 
background) mice NASH model and human NASH liver samples. These samples also 
showed increased GLUT4, an important glucose transporter and α-SMA a marker of 
activated HSC’s. mRNA and protein levels, interestingly GLUT4 was expressed in the 
sinusoidal cells and was co-localized with α-SMA in both wild type mice NASH model 
and human NASH liver samples. This increase in GLUT4 and α-SMA was remarkably 
lowered in P2X7r or Leptin deficient mice indicating roles of both in activation of HSC’s 
via glucose uptake. Since glucose levels in cells are tightly controlled by Insulin signaling 
in cells which activates the AKT pathway, we looked at p-AKT levels in the NASH mice 
and found that there was significant increase in the levels of p-AKT in the wild type NASH 
mice with significantly lower levels in Leptin and P2X7r KO mice, indicating that they 
may be able to control glucose levels via AKT activation. This was proved by treating the 
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HSC’s in-vitro with specific P2X7r Agonists and P7 Antagonists in the presence or absence 
of Leptin along with an AKT inhibitor. In-vitro experiments showed that Leptin could 
stimulate P2X7r leading to AKT phosphorylation. AKT phosphorylation is necessary for 
induction of GLUT4, and subsequent glucose import in the HSC’s. Increased glucose 
levels lead to HSC activation in NASH. This was the first study that elucidates the role of 
Leptin mediated P2X7r activation leading to GLUT4 induction activating HSC in a murine 
and human NASH liver samples (24). This research opened an interesting mechanism for 
HSC activation by Leptin-P2X7r-GLUT4 axis leading to hepatic injury. Thus, P2X7r can 
be considered an important therapeutic target in the treatment of NASH. 
Along with the mechanism for liver injury, I also explored the possibility of the 
fatty liver being able to affect other organ systems, in this study I specifically looked at 
how the NAFLD liver could affect the intestines. Although there are many reports 
establishing the liver as the secondary metastatic site for intestinal cancers (183-187), 
however very few studies have explored the possibility of the NAFLD liver able to cause 
inflammation and cancer in the intestines. NAFLD liver can release a lot of Damage 
associated molecular patterns (DAMP’s) from necrotic cells due to the oxidative stress and 
severe inflammation. These DAMP’s can enter circulation and reach distant organs. We 
were the first group to show that HMGB1, a DAMP is released through the hepatic resident 
macrophage cells (Kupffer cells) by a process called pyroptosis, this HMGB1 released is 
stable in circulation and can cause inflammation by binding to and activating RAGE 
receptors in the intestines.  
Previous studies have identified macrophages are able to release HMGB1 as a 
proinflammatory cytokine (141, 188). Interestingly, I found that levels of HMGB1 was 
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dramatically higher in serum from NAFLD mice and levels were significantly lower in the 
P2X7r KO mice. mRNA and protein expression of HMGB1 co-related to the levels of 
HMGB1 found in the serum. Concurrently we see an increase in Kupffer cell activation in 
the liver evidenced by an increase in CD68 and monocyte chemoattractant protein 1 
(MCP1) in the NAFLD liver which was lower in the P2X7r KO mice. Since P2X7r leads 
to a unique form of cell death called pyroptosis by activating the NLRP3 inflammasome. 
Mechanistically, using immortalized rat Kupffer cells and liver tissue from wild type and 
P2X7r KO mice fed on a high fat diet, I have shown P2X7r stimulation is able to cause 
HMGB1 release via pyroptosis by the NLRP3 inflammasome, as evidenced by the 
membrane translocation of Gasdermin D and the co-localisation of NLRP3 with Caspase1 
and ASC2. This along with the detection of HMGB1, LDH and IL-1β in the supernatant of 
P2X7r stimulated cells confirms Pyroptosis due to P2X7r stimulation as a means for 
systemic HMGB1 release in NAFLD.  
HMGB1 extracellularly acts as a pro-inflammatory cytokine which mediates its 
effects by binding to TLR-4 and RAGE. In this study I have shown HMGB1 preferentially 
and selectively binds to RAGE receptors. Previous studies have shown that HMGB1-
RAGE binding is able to activate NOX2 enzyme complex (36, 179). We showed similar 
results as evidenced by successful assembly of the NADPH oxidase complex at the cell 
membrane. Also, a previous study by our group, showed that NADPH oxidase can recruit 
TLR-4 to the lipid rafts of the cell membrane via peroxynitrite production (189). However, 
the exact mechanism for the same is unknown. Using a p47Phox KO mice model treated 
like the NAFLD group we showed that TLR-4 recruitment to lipid rafts is indeed dependent 
on NADPH oxidase. Activated NADPH oxidase generates Peroxynitrite, which is a highly 
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reactive compound which causes protein nitration, using immortalized rat intestinal 
epithelial cells I have shown here that peroxynitrite can cause transient phosphorylation of 
AKT, possibly by inactivating PTEN. Phosphorylated AKT is then able to recruit TLR-4 
to the lipid rafts of the cell membrane. Once TLR-4 is recruited to the cell membrane it is 
then able to bind to its ligands HMGB1 and LPS which are present in high levels in the 
underlying conditions of NAFLD leading to release of inflammatory cytokines IL-1β and 
IL6. Using a destroyed HMGB1 sample I showed that TLR-4 recruitment is dependent on 
HMGB-1-RAGE binding as shown by decrease in TLR-4 co-localization with Flotilin in 
the lipid rafts with use of either destroyed HMGB1 or RAGE An. 
This study shows a novel mechanism for cross talk between the liver and the 
intestines and sheds more light on the systemic damage that could be caused due to 
NAFLD. Our group has also recently used a natural plant based product called Sparstolonin 
B which is a potent TLR-4 antagonist, results from our group has shown to be a strong anti-
inflammatory and antifibrogenic pharmaceutical mediator (189-191). HMGB1 antibodies 
have already being used as therapeutic interventions in brain injury and arthiritis (192, 
193).  This in combination with the use of RAGE antagonists or P2X7r inhibitors could 
serve as an effective anti-inflammatory mediation in metabolic disorders such as NASH. 
Although intervention strategies help in remediation of NAFLD, early detection is key as 
these patients are largely asymptomatic. With the rates of obesity doubling every year. It 
is imperative that public awareness about NAFLD and the impact it can have on human 
health be raised.   Periodic checkups for liver enzymes at individual and community level 
should be encouraged for early diagnosis and remediation. The state can also help by 
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encouraging healthy eating habits in schools and the community and building sidewalks 
and playgrounds for citizens to adopt a healthy and active lifestyle.
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